Disease modification in Parkinsonism: obstacles and ways forward

go back to reference Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Sue LI, Jacobson SA, Belden CM, Dugger BN (2014) Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 83(5):406–412PubMedPubMedCentral Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Sue LI, Jacobson SA, Belden CM, Dugger BN (2014) Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 83(5):406–412PubMedPubMedCentral

go back to reference Alam P, Bousset L, Melki R, Otzen DE (2019) α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochem 150(5):522–534PubMed Alam P, Bousset L, Melki R, Otzen DE (2019) α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochem 150(5):522–534PubMed

go back to reference Arnaldi D, Mattioli P, Famà F, Girtler N, Brugnolo A, Pardini M, Donniaquio A, Massa F, Orso B, Raffa S, Bauckneht M, Morbelli S, Nobili F (2022) Stratification tools for disease-modifying trials in prodromal synucleinopathy. Movement Disord 37(1):52–61PubMed Arnaldi D, Mattioli P, Famà F, Girtler N, Brugnolo A, Pardini M, Donniaquio A, Massa F, Orso B, Raffa S, Bauckneht M, Morbelli S, Nobili F (2022) Stratification tools for disease-modifying trials in prodromal synucleinopathy. Movement Disord 37(1):52–61PubMed

go back to reference Atarashi R (2022) RT-QuIC as ultrasensitive method for prion detection. Cell Tissue Res. https://doi.org/10.1007/s00441-021-03568-8CrossRefPubMed Atarashi R (2022) RT-QuIC as ultrasensitive method for prion detection. Cell Tissue Res. https://​doi.​org/​10.​1007/​s00441-021-03568-8CrossRefPubMed

go back to reference Ayers JI, Lee J, Monteiro O, Woerman AL, Lazar AA, Condello C, Paras NA, Prusiner SB (2022) Different α-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy. Proc Nat Acad Sci USA 119(6):e2113489119PubMedPubMedCentral Ayers JI, Lee J, Monteiro O, Woerman AL, Lazar AA, Condello C, Paras NA, Prusiner SB (2022) Different α-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy. Proc Nat Acad Sci USA 119(6):e2113489119PubMedPubMedCentral

go back to reference Balzer-Geldsetzer M, Ferreira J, Odin P, Bloem BR, Meissner WG, Lorenzl S, Wittenberg M, Dodel R, Schrag A (2018) Study protocol: care of late-stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurol 18(1):185PubMedPubMedCentral Balzer-Geldsetzer M, Ferreira J, Odin P, Bloem BR, Meissner WG, Lorenzl S, Wittenberg M, Dodel R, Schrag A (2018) Study protocol: care of late-stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurol 18(1):185PubMedPubMedCentral

go back to reference Bardien S, Lesage S, Brice A, Carr J (2011) Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson’s disease. Parkinsonism Relat Disord 17(7):501–508PubMed Bardien S, Lesage S, Brice A, Carr J (2011) Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson’s disease. Parkinsonism Relat Disord 17(7):501–508PubMed

go back to reference Bargar C, Wang W, Gunzler SA, LeFevre A, Wang Z, Lerner AJ, Singh N, Tatsuoka C, Appleby B, Zhu X, Xu R, Haroutunian V, Zou W-Q, Ma J, Chen SG (2021) Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun 9(1):62PubMedPubMedCentral Bargar C, Wang W, Gunzler SA, LeFevre A, Wang Z, Lerner AJ, Singh N, Tatsuoka C, Appleby B, Zhu X, Xu R, Haroutunian V, Zou W-Q, Ma J, Chen SG (2021) Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun 9(1):62PubMedPubMedCentral

go back to reference Beavan MS, Schapira AHV (2013) Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med 45(8):511–521PubMed Beavan MS, Schapira AHV (2013) Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med 45(8):511–521PubMed

go back to reference Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J (2017) Alpha-synuclein oligomers: a new hope. Acta Neuropathol 134(6):819–838PubMedPubMedCentral Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J (2017) Alpha-synuclein oligomers: a new hope. Acta Neuropathol 134(6):819–838PubMedPubMedCentral

go back to reference Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN (2009) Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132(Pt 1):156–171PubMed Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN (2009) Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132(Pt 1):156–171PubMed

go back to reference Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2015) MDS research criteria for prodromal Parkinson’s disease. Movement Disord 30(12):1600–1611PubMed Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2015) MDS research criteria for prodromal Parkinson’s disease. Movement Disord 30(12):1600–1611PubMed

go back to reference Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE (2001) Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Movement Disord 16(4):622–630PubMed Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE (2001) Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Movement Disord 16(4):622–630PubMed

go back to reference Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211PubMed Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211PubMed

go back to reference Brás IC, Outeiro TF (2021) Alpha-Synuclein: mechanisms of release and pathology progression in synucleinopathies. Cells 10(2):375PubMedPubMedCentral Brás IC, Outeiro TF (2021) Alpha-Synuclein: mechanisms of release and pathology progression in synucleinopathies. Cells 10(2):375PubMedPubMedCentral

go back to reference Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, Palleis C, Gehmeyr M, Fietzek U, Respondek G, Sauerbeck J, Nitschmann A, Zach C, Hammes J, Barbe MT, Onur O, Jessen F, Saur D, Schroeter ML, Rumpf J-J, Rullmann M, Schildan A, Patt M, Neumaier B, Barret O, Madonia J, Russell DS, Stephens A, Roeber S, Herms J, Bötzel K, Classen J, Bartenstein P, Villemagne V, Levin J, Höglinger GU, Drzezga A, Seibyl J, Sabri O (2020) Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol 77(11):1408–1419PubMed Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, Palleis C, Gehmeyr M, Fietzek U, Respondek G, Sauerbeck J, Nitschmann A, Zach C, Hammes J, Barbe MT, Onur O, Jessen F, Saur D, Schroeter ML, Rumpf J-J, Rullmann M, Schildan A, Patt M, Neumaier B, Barret O, Madonia J, Russell DS, Stephens A, Roeber S, Herms J, Bötzel K, Classen J, Bartenstein P, Villemagne V, Levin J, Höglinger GU, Drzezga A, Seibyl J, Sabri O (2020) Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol 77(11):1408–1419PubMed

go back to reference Brendel M, Deussing M, Blume T, Kaiser L, Probst F, Overhoff F, Peters F, von Ungern-Sternberg B, Ryazanov S, Leonov A, Griesinger C, Zwergal A, Levin J, Bartenstein P, Yakushev I, Cumming P, Boening G, Ziegler S, Herms J, Giese A, Rominger A (2019) Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau. Alzheimer’s Res Ther 11(1):67 Brendel M, Deussing M, Blume T, Kaiser L, Probst F, Overhoff F, Peters F, von Ungern-Sternberg B, Ryazanov S, Leonov A, Griesinger C, Zwergal A, Levin J, Bartenstein P, Yakushev I, Cumming P, Boening G, Ziegler S, Herms J, Giese A, Rominger A (2019) Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau. Alzheimer’s Res Ther 11(1):67

go back to reference Bruch J, Kurz C, Vasiljevic A, Nicolino M, Arzberger T, Höglinger GU (2015) Early neurodegeneration in the brain of a child without functional PKR-like endoplasmic reticulum kinase. J Neuropathol Exp Neurol 74(8):850–857PubMed Bruch J, Kurz C, Vasiljevic A, Nicolino M, Arzberger T, Höglinger GU (2015) Early neurodegeneration in the brain of a child without functional PKR-like endoplasmic reticulum kinase. J Neuropathol Exp Neurol 74(8):850–857PubMed

go back to reference Bruch J, Xu H, Rösler TW, de Andrade A, Kuhn P-H, Lichtenthaler SF, Arzberger T, Winklhofer KF, Müller U, Höglinger GU (2017) PERK activation mitigates tau pathology in vitro and in vivo. EMBO Mol Med 9(3):371–384PubMedPubMedCentral Bruch J, Xu H, Rösler TW, de Andrade A, Kuhn P-H, Lichtenthaler SF, Arzberger T, Winklhofer KF, Müller U, Höglinger GU (2017) PERK activation mitigates tau pathology in vitro and in vivo. EMBO Mol Med 9(3):371–384PubMedPubMedCentral

go back to reference Brunello CA, Merezhko M, Uronen R-L, Huttunen HJ (2020) Mechanisms of secretion and spreading of pathological tau protein. Cell Mol Life Sci 77(9):1721–1744PubMed Brunello CA, Merezhko M, Uronen R-L, Huttunen HJ (2020) Mechanisms of secretion and spreading of pathological tau protein. Cell Mol Life Sci 77(9):1721–1744PubMed

go back to reference Bruno V, Mancini D, Ghoche R, Arshinoff R, Miyasaki JM (2016) High prevalence of physical and sexual aggression to caregivers in advanced Parkinson’s disease. Experience in the Palliative Care Program. Parkinsonism Relat Disord 24:141–142PubMed Bruno V, Mancini D, Ghoche R, Arshinoff R, Miyasaki JM (2016) High prevalence of physical and sexual aggression to caregivers in advanced Parkinson’s disease. Experience in the Palliative Care Program. Parkinsonism Relat Disord 24:141–142PubMed

go back to reference Bükki J, Nübling G, Lorenzl S (2016) Managing advanced progressive supranuclear palsy and corticobasal degeneration in a palliative care unit: admission triggers and outcomes. Am J Hosp Palliat Care 33(5):477–482PubMed Bükki J, Nübling G, Lorenzl S (2016) Managing advanced progressive supranuclear palsy and corticobasal degeneration in a palliative care unit: admission triggers and outcomes. Am J Hosp Palliat Care 33(5):477–482PubMed

go back to reference Calafate S, Flavin W, Verstreken P, Moechars D (2016) Loss of Bin1 promotes the propagation of tau pathology. Cell Rep 17(4):931–940PubMed Calafate S, Flavin W, Verstreken P, Moechars D (2016) Loss of Bin1 promotes the propagation of tau pathology. Cell Rep 17(4):931–940PubMed

go back to reference Candelise N, Schmitz M, Da Silva Correia SM, Arora AS, Villar-Piqué A, Zafar S, Llorens F, Cramm M, Zerr I (2017) Applications of the real-time quaking-induced conversion assay in diagnosis, prion strain-typing, drug pre-screening and other amyloidopathies. Expert Rev Mol Diagn 17(10):897–904PubMed Candelise N, Schmitz M, Da Silva Correia SM, Arora AS, Villar-Piqué A, Zafar S, Llorens F, Cramm M, Zerr I (2017) Applications of the real-time quaking-induced conversion assay in diagnosis, prion strain-typing, drug pre-screening and other amyloidopathies. Expert Rev Mol Diagn 17(10):897–904PubMed

go back to reference Chahine LM, Brumm MC, Caspell-Garcia C, Oertel W, Mollenhauer B, Amara A, Fernandez-Arcos A, Tolosa E, Simonet C, Hogl B, Videnovic A, Hutten SJ, Tanner C, Weintraub D, Burghardt E, Coffey C, Cho HR, Kieburtz K, Poston KL, Merchant K, Galasko D, Foroud T, Siderowf A, Marek K, Simuni T, Iranzo A (2021a) Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder. Anna Clin Transl Neurol 8(1):201–212 Chahine LM, Brumm MC, Caspell-Garcia C, Oertel W, Mollenhauer B, Amara A, Fernandez-Arcos A, Tolosa E, Simonet C, Hogl B, Videnovic A, Hutten SJ, Tanner C, Weintraub D, Burghardt E, Coffey C, Cho HR, Kieburtz K, Poston KL, Merchant K, Galasko D, Foroud T, Siderowf A, Marek K, Simuni T, Iranzo A (2021a) Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder. Anna Clin Transl Neurol 8(1):201–212

go back to reference Chahine LM, Feldman R, Althouse A, Torsney B, Alzyoud L, Mantri S, Edison B, Albert S, Daeschler M, Kopil C, Marras C (2021b) Contribution of neuropsychiatric symptoms in Parkinson’s disease to different domains of caregiver burden. J Neurol 268(8):2961–2972PubMedPubMedCentral Chahine LM, Feldman R, Althouse A, Torsney B, Alzyoud L, Mantri S, Edison B, Albert S, Daeschler M, Kopil C, Marras C (2021b) Contribution of neuropsychiatric symptoms in Parkinson’s disease to different domains of caregiver burden. J Neurol 268(8):2961–2972PubMedPubMedCentral

go back to reference Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, Zharkovsky A, Kaasik A (2011) Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 286(12):10814–10824PubMedPubMedCentral Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, Zharkovsky A, Kaasik A (2011) Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 286(12):10814–10824PubMedPubMedCentral

go back to reference Churm D, Dickinson C, Robinson L, Paes P, Cronin T, Walker R (2022) Understanding how people with Parkinson’s disease and their relatives approach advance care planning. Eur Geriatr Med 13(1):109–117PubMed Churm D, Dickinson C, Robinson L, Paes P, Cronin T, Walker R (2022) Understanding how people with Parkinson’s disease and their relatives approach advance care planning. Eur Geriatr Med 13(1):109–117PubMed

go back to reference Ciurleo R, Di Lorenzo G, Bramanti P, Marino S (2014) Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson’s disease? Biomed Res Int 2014:519816PubMedPubMedCentral Ciurleo R, Di Lorenzo G, Bramanti P, Marino S (2014) Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson’s disease? Biomed Res Int 2014:519816PubMedPubMedCentral

go back to reference Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol J-C, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O’Gorman J, Haeberlein SB (2021) Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med 27(8):1451–1457PubMed Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol J-C, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O’Gorman J, Haeberlein SB (2021) Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med 27(8):1451–1457PubMed

go back to reference Dehestani M, Liu H, Gasser T (2021) Polygenic risk scores contribute to personalized medicine of Parkinson’s Disease. J Personalized Med 11(10):1030 Dehestani M, Liu H, Gasser T (2021) Polygenic risk scores contribute to personalized medicine of Parkinson’s Disease. J Personalized Med 11(10):1030

go back to reference Dickson DW (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46(Suppl 1):S30–S33PubMed Dickson DW (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46(Suppl 1):S30–S33PubMed

go back to reference Ding X-Q, Lanfermann H (2015) Whole brain 1H-Spectroscopy: a developing technique for advanced analysis of cerebral metabolism. Clin Neuroradiol 25(Suppl 2):245–250PubMed Ding X-Q, Lanfermann H (2015) Whole brain ¹H-Spectroscopy: a developing technique for advanced analysis of cerebral metabolism. Clin Neuroradiol 25(Suppl 2):245–250PubMed

go back to reference Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, Trenkwalder C, Sixel-Döring F, Herting B, Kamm C, Gasser T, Sawires M, Geser F, Köllensperger M, Seppi K, Kloss M, Krause M, Daniels C, Deuschl G, Böttger S, Naumann M, Lipp A, Gruber D, Kupsch A, Du Y, Turkheimer F, Brooks DJ, Klockgether T, Poewe W, Wenning G, Schade-Brittinger C, Oertel WH, Eggert K (2010) Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and (11)C (R)-PK11195 PET (MEMSA-trial). Movement Disord 25(1):97–107PubMed Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, Trenkwalder C, Sixel-Döring F, Herting B, Kamm C, Gasser T, Sawires M, Geser F, Köllensperger M, Seppi K, Kloss M, Krause M, Daniels C, Deuschl G, Böttger S, Naumann M, Lipp A, Gruber D, Kupsch A, Du Y, Turkheimer F, Brooks DJ, Klockgether T, Poewe W, Wenning G, Schade-Brittinger C, Oertel WH, Eggert K (2010) Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and (11)C (R)-PK11195 PET (MEMSA-trial). Movement Disord 25(1):97–107PubMed

go back to reference Doppler K (2021) Detection of dermal alpha-synuclein deposits as a biomarker for Parkinson’s Disease. J Parkinsons Dis 11(3):937–947PubMedPubMedCentral Doppler K (2021) Detection of dermal alpha-synuclein deposits as a biomarker for Parkinson’s Disease. J Parkinsons Dis 11(3):937–947PubMedPubMedCentral

go back to reference Doppler K, Jentschke H-M, Schulmeyer L, Vadasz D, Janzen A, Luster M, Höffken H, Mayer G, Brumberg J, Booij J, Musacchio T, Klebe S, Sittig-Wiegand E, Volkmann J, Sommer C, Oertel WH (2017) Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease. Acta Neuropathol 133(4):535–545PubMedPubMedCentral Doppler K, Jentschke H-M, Schulmeyer L, Vadasz D, Janzen A, Luster M, Höffken H, Mayer G, Brumberg J, Booij J, Musacchio T, Klebe S, Sittig-Wiegand E, Volkmann J, Sommer C, Oertel WH (2017) Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease. Acta Neuropathol 133(4):535–545PubMedPubMedCentral

go back to reference von Eichel H, Heine J, Wegner F, Rogozinski S, Stiel S, Groh A, Krey L, Höglinger GU, Klietz M (2022) Neuropsychiatric symptoms in Parkinson’s disease patients are associated with reduced health-related quality of life and increased caregiver burden. Brain Sci 12(1):89PubMed von Eichel H, Heine J, Wegner F, Rogozinski S, Stiel S, Groh A, Krey L, Höglinger GU, Klietz M (2022) Neuropsychiatric symptoms in Parkinson’s disease patients are associated with reduced health-related quality of life and increased caregiver burden. Brain Sci 12(1):89PubMed

go back to reference Emmenegger M, de Cecco E, Hruska-Plochan M, Eninger T, Schneider MM, Barth M, Tantardini E, de Rossi P, Bacioglu M, Langston RG, Kaganovich A, Bengoa-Vergniory N, Gonzalez-Guerra A, Avar M, Heinzer D, Reimann R, Häsler LM, Herling TW, Matharu NS, Landeck N, Luk K, Melki R, Kahle PJ, Hornemann S, Knowles TPJ, Cookson MR, Polymenidou M, Jucker M, Aguzzi A (2021) LAG3 is not expressed in human and murine neurons and does not modulate α-synucleinopathies. EMBO Mol Med 13(9):e14745PubMedPubMedCentral Emmenegger M, de Cecco E, Hruska-Plochan M, Eninger T, Schneider MM, Barth M, Tantardini E, de Rossi P, Bacioglu M, Langston RG, Kaganovich A, Bengoa-Vergniory N, Gonzalez-Guerra A, Avar M, Heinzer D, Reimann R, Häsler LM, Herling TW, Matharu NS, Landeck N, Luk K, Melki R, Kahle PJ, Hornemann S, Knowles TPJ, Cookson MR, Polymenidou M, Jucker M, Aguzzi A (2021) LAG3 is not expressed in human and murine neurons and does not modulate α-synucleinopathies. EMBO Mol Med 13(9):e14745PubMedPubMedCentral

go back to reference Fanciulli A, Wenning GK (2015) Multiple-system atrophy. N Engl J Med 372(3):249–263PubMed Fanciulli A, Wenning GK (2015) Multiple-system atrophy. N Engl J Med 372(3):249–263PubMed

go back to reference Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283–2301PubMed Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283–2301PubMed

go back to reference Fellner L, Kuzdas-Wood D, Levin J, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N (2016) Anle138b partly ameliorates motor deficits despite failure of neuroprotection in a model of advanced multiple system atrophy. Front Neurosci 10:99PubMedPubMedCentral Fellner L, Kuzdas-Wood D, Levin J, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N (2016) Anle138b partly ameliorates motor deficits despite failure of neuroprotection in a model of advanced multiple system atrophy. Front Neurosci 10:99PubMedPubMedCentral

go back to reference Feng Y, He D, Yao Z, Klionsky DJ (2014) The machinery of macroautophagy. Cell Res 24(1):24–41PubMed Feng Y, He D, Yao Z, Klionsky DJ (2014) The machinery of macroautophagy. Cell Res 24(1):24–41PubMed

go back to reference Fereshtehnejad S-M, Zeighami Y, Dagher A, Postuma RB (2017) Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. Brain 140(7):1959–1976PubMed Fereshtehnejad S-M, Zeighami Y, Dagher A, Postuma RB (2017) Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. Brain 140(7):1959–1976PubMed

go back to reference Fernandes L, Cardim-Pires TR, Foguel D, Palhano FL (2021) Green tea polyphenol epigallocatechin-gallate in amyloid aggregation and neurodegenerative diseases. Front Neurosci 15:718188PubMedPubMedCentral Fernandes L, Cardim-Pires TR, Foguel D, Palhano FL (2021) Green tea polyphenol epigallocatechin-gallate in amyloid aggregation and neurodegenerative diseases. Front Neurosci 15:718188PubMedPubMedCentral

go back to reference Fleming A, Bourdenx M, Fujimaki M, Karabiyik C, Krause GJ, Lopez A, Martín-Segura A, Puri C, Scrivo A, Skidmore J, Son SM, Stamatakou E, Wrobel L, Zhu Y, Cuervo AM, Rubinsztein DC (2022) The different autophagy degradation pathways and neurodegeneration. Neuron 110(6):935–966PubMed Fleming A, Bourdenx M, Fujimaki M, Karabiyik C, Krause GJ, Lopez A, Martín-Segura A, Puri C, Scrivo A, Skidmore J, Son SM, Stamatakou E, Wrobel L, Zhu Y, Cuervo AM, Rubinsztein DC (2022) The different autophagy degradation pathways and neurodegeneration. Neuron 110(6):935–966PubMed

go back to reference Folke J, Rydbirk R, Løkkegaard A, Hejl A-M, Winge K, Starhof C, Salvesen L, Pedersen LØ, Aznar S, Pakkenberg B, Brudek T (2021) Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson’s disease. Parkinsonism Relat Disord 87:98–104PubMed Folke J, Rydbirk R, Løkkegaard A, Hejl A-M, Winge K, Starhof C, Salvesen L, Pedersen LØ, Aznar S, Pakkenberg B, Brudek T (2021) Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson’s disease. Parkinsonism Relat Disord 87:98–104PubMed

go back to reference Foubert-Samier A, Pavy-Le Traon A, Guillet F, Le-Goff M, Helmer C, Tison F, Rascol O, Proust-Lima C, Meissner WG (2020) Disease progression and prognostic factors in multiple system atrophy: a prospective cohort study. Neurobiol Dis 139:104813PubMed Foubert-Samier A, Pavy-Le Traon A, Guillet F, Le-Goff M, Helmer C, Tison F, Rascol O, Proust-Lima C, Meissner WG (2020) Disease progression and prognostic factors in multiple system atrophy: a prospective cohort study. Neurobiol Dis 139:104813PubMed

go back to reference Fowler AJ, Moussa CE-H (2018) Activating autophagy as a therapeutic strategy for Parkinson’s disease. CNS Drugs 32(1):1–11PubMed Fowler AJ, Moussa CE-H (2018) Activating autophagy as a therapeutic strategy for Parkinson’s disease. CNS Drugs 32(1):1–11PubMed

go back to reference Frank A, Peikert K, Linn J, Brandt MD, Hermann A (2020) MDS criteria for the diagnosis of progressive supranuclear palsy overemphasize Richardson syndrome. Ann Clin Transl Neurol 7(9):1702–1707PubMedPubMedCentral Frank A, Peikert K, Linn J, Brandt MD, Hermann A (2020) MDS criteria for the diagnosis of progressive supranuclear palsy overemphasize Richardson syndrome. Ann Clin Transl Neurol 7(9):1702–1707PubMedPubMedCentral

go back to reference Fussi N, Höllerhage M, Chakroun T, Nykänen N-P, Rösler TW, Koeglsperger T, Wurst W, Behrends C, Höglinger GU (2018) Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy. Cell Death Dis 9(7):757PubMedPubMedCentral Fussi N, Höllerhage M, Chakroun T, Nykänen N-P, Rösler TW, Koeglsperger T, Wurst W, Behrends C, Höglinger GU (2018) Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy. Cell Death Dis 9(7):757PubMedPubMedCentral

go back to reference Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D (2011) The patients’ perception of prodromal symptoms before the initial diagnosis of Parkinson’s disease. Movement Disord 26(4):653–658PubMed Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D (2011) The patients’ perception of prodromal symptoms before the initial diagnosis of Parkinson’s disease. Movement Disord 26(4):653–658PubMed

go back to reference Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870–881PubMed Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870–881PubMed

go back to reference Gatsios D, Antonini A, Gentile G, Konitsiotis S, Fotiadis D, Nixina I, Taba P, Weck C, Lorenzl S, Lex KM, Paal P (2021) Education on palliative care for Parkinson patients: development of the “Best care for people with late-stage Parkinson’s disease” curriculum toolkit. BMC Med Educ 21(1):538PubMedPubMedCentral Gatsios D, Antonini A, Gentile G, Konitsiotis S, Fotiadis D, Nixina I, Taba P, Weck C, Lorenzl S, Lex KM, Paal P (2021) Education on palliative care for Parkinson patients: development of the “Best care for people with late-stage Parkinson’s disease” curriculum toolkit. BMC Med Educ 21(1):538PubMedPubMedCentral

go back to reference Genç F, Yuksel B, Tokuc FEU (2019) Caregiver burden and quality of life in early and late stages of idiopathic Parkinson’s disease. Psychiatry Investig 16(4):285–291PubMedPubMedCentral Genç F, Yuksel B, Tokuc FEU (2019) Caregiver burden and quality of life in early and late stages of idiopathic Parkinson’s disease. Psychiatry Investig 16(4):285–291PubMedPubMedCentral

go back to reference Giannini G, Mastrangelo V, Provini F, Droghini A, Cecere A, Barletta G, Mignani F, Guaraldi P, Cortelli P, Calandra-Buonaura G (2020) Progression and prognosis in multiple system atrophy presenting with REM behavior disorder. Neurology 94(17):e1828–e1834PubMed Giannini G, Mastrangelo V, Provini F, Droghini A, Cecere A, Barletta G, Mignani F, Guaraldi P, Cortelli P, Calandra-Buonaura G (2020) Progression and prognosis in multiple system atrophy presenting with REM behavior disorder. Neurology 94(17):e1828–e1834PubMed

go back to reference Giannoccaro MP, Avoni P, Rizzo G, Incensi A, Infante R, Donadio V, Liguori R (2022) Presence of skin α-Synuclein deposits discriminates Parkinson’s disease from progressive supranuclear palsy and corticobasal syndrome. J Parkinsons Dis 12(2):585–591PubMedPubMedCentral Giannoccaro MP, Avoni P, Rizzo G, Incensi A, Infante R, Donadio V, Liguori R (2022) Presence of skin α-Synuclein deposits discriminates Parkinson’s disease from progressive supranuclear palsy and corticobasal syndrome. J Parkinsons Dis 12(2):585–591PubMedPubMedCentral

go back to reference Goedert M, Spillantini MG, Del Tredici K, Braak H (2013) 100 years of Lewy pathology. Nat Rev Neurol 9(1):13–24PubMed Goedert M, Spillantini MG, Del Tredici K, Braak H (2013) 100 years of Lewy pathology. Nat Rev Neurol 9(1):13–24PubMed

go back to reference Greten S, Müller-Funogea JI, Wegner F, Höglinger GU, Simon N, Junius-Walker U, Gerbel S, Krause O, Klietz M (2021) Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis. J Neural Trans (vienna, Austria: 1996) 128(1):49–60 Greten S, Müller-Funogea JI, Wegner F, Höglinger GU, Simon N, Junius-Walker U, Gerbel S, Krause O, Klietz M (2021) Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis. J Neural Trans (vienna, Austria: 1996) 128(1):49–60

go back to reference Grimm M-J, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol J-C, Lang AE, Rowe JB, Höglinger GU (2019) How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disord 34(8):1228–1232PubMed Grimm M-J, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol J-C, Lang AE, Rowe JB, Höglinger GU (2019) How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disord 34(8):1228–1232PubMed

go back to reference Grimm M-J, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Meissner WG, Nilsson C, Piot I, Compta Y, Rowe JB, Höglinger GU (2020) Clinical conditions “suggestive of progressive supranuclear palsy”-diagnostic performance. Movement Disord 35(12):2301–2313PubMed Grimm M-J, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Meissner WG, Nilsson C, Piot I, Compta Y, Rowe JB, Höglinger GU (2020) Clinical conditions “suggestive of progressive supranuclear palsy”-diagnostic performance. Movement Disord 35(12):2301–2313PubMed

go back to reference Grötsch M-T, Respondek G, Colosimo C, Compta Y, Corvol JC, Ferreira J, Huber MK, Klietz M, Krey LFM, Levin J, Jecmenica-Lukic M, Macías-García D, Meissner WG, Mir P, Morris H, Nilsson C, Rowe JB, Seppi K, Stamelou M, van Swieten JC, Wenning G, Del Ser T, Golbe LI, Höglinger GU (2021) A modified progressive supranuclear palsy rating scale. Movement Disord 36(5):1203–1215PubMed Grötsch M-T, Respondek G, Colosimo C, Compta Y, Corvol JC, Ferreira J, Huber MK, Klietz M, Krey LFM, Levin J, Jecmenica-Lukic M, Macías-García D, Meissner WG, Mir P, Morris H, Nilsson C, Rowe JB, Seppi K, Stamelou M, van Swieten JC, Wenning G, Del Ser T, Golbe LI, Höglinger GU (2021) A modified progressive supranuclear palsy rating scale. Movement Disord 36(5):1203–1215PubMed

go back to reference Grün D, Pieri V, Vaillant M, Diederich NJ (2016) Contributory factors to caregiver burden in Parkinson disease. J Am Med Dir Assoc 17(7):626–632PubMed Grün D, Pieri V, Vaillant M, Diederich NJ (2016) Contributory factors to caregiver burden in Parkinson disease. J Am Med Dir Assoc 17(7):626–632PubMed

go back to reference Guasp M, Molina-Porcel L, Painous C, Caballol N, Camara A, Perez-Soriano A, Sánchez-Gómez A, Garrido A, Muñoz E, Marti MJ, Valldeoriola F, Grau O, Gelpí E, Respondek G, Höglinger GH, Compta Y (2021) Association of PSP phenotypes with survival: a brain-bank study. Parkinsonism Relat Disord 84:77–81PubMed Guasp M, Molina-Porcel L, Painous C, Caballol N, Camara A, Perez-Soriano A, Sánchez-Gómez A, Garrido A, Muñoz E, Marti MJ, Valldeoriola F, Grau O, Gelpí E, Respondek G, Höglinger GH, Compta Y (2021) Association of PSP phenotypes with survival: a brain-bank study. Parkinsonism Relat Disord 84:77–81PubMed

go back to reference Heine J, von Eichel H, Staege S, Höglinger GU, Wegner F, Klietz M (2021) Relationship satisfaction in people with Parkinson’s disease and their caregivers: a cross-sectional observational study. Brain Sci 11(6):822PubMedPubMedCentral Heine J, von Eichel H, Staege S, Höglinger GU, Wegner F, Klietz M (2021) Relationship satisfaction in people with Parkinson’s disease and their caregivers: a cross-sectional observational study. Brain Sci 11(6):822PubMedPubMedCentral

go back to reference Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB (2019) Update of the MDS research criteria for prodromal Parkinson’s disease. Movement Disord 34(10):1464–1470PubMed Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB (2019) Update of the MDS research criteria for prodromal Parkinson’s disease. Movement Disord 34(10):1464–1470PubMed

go back to reference Hellqvist C, Berterö C, Dizdar N, Sund-Levander M, Hagell P (2020) Self-management education for persons with parkinson’s disease and their care partners: a quasi-experimental case-control study in clinical practice. Parkinson’s Dis 2020:6920943 Hellqvist C, Berterö C, Dizdar N, Sund-Levander M, Hagell P (2020) Self-management education for persons with parkinson’s disease and their care partners: a quasi-experimental case-control study in clinical practice. Parkinson’s Dis 2020:6920943

go back to reference Hellqvist C, Dizdar N, Hagell P, Berterö C, Sund-Levander M (2018) Improving self-management for persons with Parkinson’s disease through education focusing on management of daily life: patients’ and relatives’ experience of the Swedish National Parkinson School. J Clin Nurs 27(19–20):3719–3728PubMed Hellqvist C, Dizdar N, Hagell P, Berterö C, Sund-Levander M (2018) Improving self-management for persons with Parkinson’s disease through education focusing on management of daily life: patients’ and relatives’ experience of the Swedish National Parkinson School. J Clin Nurs 27(19–20):3719–3728PubMed

go back to reference Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N (2019) Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Movement Disord 34(2):255–263PubMed Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N (2019) Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Movement Disord 34(2):255–263PubMed

go back to reference Hermann P, Appleby B, Brandel J-P, Caughey B, Collins S, Geschwind MD, Green A, Haïk S, Kovacs GG, Ladogana A, Llorens F, Mead S, Nishida N, Pal S, Parchi P, Pocchiari M, Satoh K, Zanusso G, Zerr I (2021) Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol 20(3):235–246PubMedPubMedCentral Hermann P, Appleby B, Brandel J-P, Caughey B, Collins S, Geschwind MD, Green A, Haïk S, Kovacs GG, Ladogana A, Llorens F, Mead S, Nishida N, Pal S, Parchi P, Pocchiari M, Satoh K, Zanusso G, Zerr I (2021) Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol 20(3):235–246PubMedPubMedCentral

go back to reference Höglinger GU, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B, Lon H-K, Jin Z, Fisseha N, Budur K, Gold M, Ryman D, Florian H, Ahmed A, Aiba I, Albanese A, Bertram K, Bordelon Y, Bower J, Brosch J, Claassen D, Colosimo C, Corvol J-C, Cudia P, Daniele A, Defebvre L, Driver-Dunckley E, Duquette A, Eleopra R, Eusebio A, Fung V, Geldmacher D, Golbe L, Grandas F, Hall D, Hatano T, Honig L, Hui J, Kerwin D, Kikuchi A, Kimber T, Kimura T, Kumar R, Ljubenkov P, Lorenzl S, Ludolph A, Mari Z, McFarland N, Meissner W, Mir Rivera P, Mochizuki H, Morgan J, Munhoz R, Nishikawa N, O’Sullivan J, Oeda T, Oizumi H, Onodera O, Ory-Magne F, Peckham E, Postuma R, Quattrone A, Quinn J, Ruggieri S, Sarna J, Schulz PE, Slevin J, Tagliati M, Wile D, Wszolek Z, Xie T, Zesiewicz T (2021) Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol 20(3):182–192PubMed Höglinger GU, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B, Lon H-K, Jin Z, Fisseha N, Budur K, Gold M, Ryman D, Florian H, Ahmed A, Aiba I, Albanese A, Bertram K, Bordelon Y, Bower J, Brosch J, Claassen D, Colosimo C, Corvol J-C, Cudia P, Daniele A, Defebvre L, Driver-Dunckley E, Duquette A, Eleopra R, Eusebio A, Fung V, Geldmacher D, Golbe L, Grandas F, Hall D, Hatano T, Honig L, Hui J, Kerwin D, Kikuchi A, Kimber T, Kimura T, Kumar R, Ljubenkov P, Lorenzl S, Ludolph A, Mari Z, McFarland N, Meissner W, Mir Rivera P, Mochizuki H, Morgan J, Munhoz R, Nishikawa N, O’Sullivan J, Oeda T, Oizumi H, Onodera O, Ory-Magne F, Peckham E, Postuma R, Quattrone A, Quinn J, Ruggieri S, Sarna J, Schulz PE, Slevin J, Tagliati M, Wile D, Wszolek Z, Xie T, Zesiewicz T (2021) Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol 20(3):182–192PubMed

go back to reference Höglinger GU, Melhem NM, Dickson DW, Sleiman PMA, Wang L-S, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu C-E, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43(7):699–705PubMedPubMedCentral Höglinger GU, Melhem NM, Dickson DW, Sleiman PMA, Wang L-S, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu C-E, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43(7):699–705PubMedPubMedCentral

go back to reference Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol J-C, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Movement Disord 32(6):853–864PubMed Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol J-C, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Movement Disord 32(6):853–864PubMed

go back to reference Höllerhage M, Fussi N, Rösler TW, Wurst W, Behrends C, Höglinger GU (2019) Multiple molecular pathways stimulating macroautophagy protect from alpha-synuclein-induced toxicity in human neurons. Neuropharmacology 149:13–26PubMed Höllerhage M, Fussi N, Rösler TW, Wurst W, Behrends C, Höglinger GU (2019) Multiple molecular pathways stimulating macroautophagy protect from alpha-synuclein-induced toxicity in human neurons. Neuropharmacology 149:13–26PubMed

go back to reference Höllerhage M, Goebel JN, de Andrade A, Hildebrandt T, Dolga A, Culmsee C, Oertel WH, Hengerer B, Höglinger GU (2014) Trifluoperazine rescues human dopaminergic cells from wild-type α-synuclein-induced toxicity. Neurobiol Aging 35(7):1700–1711PubMed Höllerhage M, Goebel JN, de Andrade A, Hildebrandt T, Dolga A, Culmsee C, Oertel WH, Hengerer B, Höglinger GU (2014) Trifluoperazine rescues human dopaminergic cells from wild-type α-synuclein-induced toxicity. Neurobiol Aging 35(7):1700–1711PubMed

go back to reference Höllerhage M, Moebius C, Melms J, Chiu W-H, Goebel JN, Chakroun T, Koeglsperger T, Oertel WH, Rösler TW, Bickle M, Höglinger GU (2017) Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. Sci Rep 7(1):11469PubMedPubMedCentral Höllerhage M, Moebius C, Melms J, Chiu W-H, Goebel JN, Chakroun T, Koeglsperger T, Oertel WH, Rösler TW, Bickle M, Höglinger GU (2017) Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. Sci Rep 7(1):11469PubMedPubMedCentral

go back to reference Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA 110(33):E3138–E3147PubMedPubMedCentral Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA 110(33):E3138–E3147PubMedPubMedCentral

go back to reference Hommel ALAJ, Meinders MJ, Lorenzl S, Dodel R, Coelho M, Ferreira JJ, Laurens B, Spampinato U, Meissner W, Rosqvist K, Timpka J, Odin P, Wittenberg M, Bloem PhD BR, Koopmans RT, Schrag A (2020) The prevalence and determinants of neuropsychiatric symptoms in late-stage Parkinsonism. Movement Disord Clin Pract 7(5):531–542 Hommel ALAJ, Meinders MJ, Lorenzl S, Dodel R, Coelho M, Ferreira JJ, Laurens B, Spampinato U, Meissner W, Rosqvist K, Timpka J, Odin P, Wittenberg M, Bloem PhD BR, Koopmans RT, Schrag A (2020) The prevalence and determinants of neuropsychiatric symptoms in late-stage Parkinsonism. Movement Disord Clin Pract 7(5):531–542

go back to reference Hopfner F, Tietz AK, Ruf V, Ross OA, Koga S, Dickson D, Aguzzi A, Attems J, Beach T, Beller A, van Deerlin V, Desplats P, Deuschl G, Duyckaerts C, Ellinghaus D, Evsyukov V, Flanagan ME, Franke A, Frosch MP, Gearing M, Gelpi E, Ghetti B, Glass JD, Grinberg LT, Halliday G, Helbig I, Höllerhage M, Huitinga I, Irwin DJ, Keene DC, Kovacs GG, Lee EB, Levin J, Martí MJ, Mackenzie I, McKeith I, McLean C, Mollenhauer B, Neumann M, Newell KL, Pantelyat A, Pendziwiat M, Peters A, Porcel LM, Rabano A, Matěj R, Rajput A, Rajput A, Reimann R, Scott WK, Seeley W, Selvackadunco S, Simuni T, Stadelmann C, Svenningsson P, Thomas A, Trenkwalder C, Troakes C, Trojanowski JQ, White CL, Xie T, Ximelis T, Yebenes J, Müller U, Schellenberg GD, Herms J, Kuhlenbäumer G, Höglinger G (2022) Common variants near ZIC1 and ZIC4 in autopsy-confirmed Multiple System Atrophy. Movement Disord (in press) Hopfner F, Tietz AK, Ruf V, Ross OA, Koga S, Dickson D, Aguzzi A, Attems J, Beach T, Beller A, van Deerlin V, Desplats P, Deuschl G, Duyckaerts C, Ellinghaus D, Evsyukov V, Flanagan ME, Franke A, Frosch MP, Gearing M, Gelpi E, Ghetti B, Glass JD, Grinberg LT, Halliday G, Helbig I, Höllerhage M, Huitinga I, Irwin DJ, Keene DC, Kovacs GG, Lee EB, Levin J, Martí MJ, Mackenzie I, McKeith I, McLean C, Mollenhauer B, Neumann M, Newell KL, Pantelyat A, Pendziwiat M, Peters A, Porcel LM, Rabano A, Matěj R, Rajput A, Rajput A, Reimann R, Scott WK, Seeley W, Selvackadunco S, Simuni T, Stadelmann C, Svenningsson P, Thomas A, Trenkwalder C, Troakes C, Trojanowski JQ, White CL, Xie T, Ximelis T, Yebenes J, Müller U, Schellenberg GD, Herms J, Kuhlenbäumer G, Höglinger G (2022) Common variants near ZIC1 and ZIC4 in autopsy-confirmed Multiple System Atrophy. Movement Disord (in press)

go back to reference Iranzo A, Fairfoul G, Ayudhaya ACN, Serradell M, Gelpi E, Vilaseca I, Sanchez-Valle R, Gaig C, Santamaria J, Tolosa E, Riha RL, Green AJE (2021) Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol 20(3):203–212PubMed Iranzo A, Fairfoul G, Ayudhaya ACN, Serradell M, Gelpi E, Vilaseca I, Sanchez-Valle R, Gaig C, Santamaria J, Tolosa E, Riha RL, Green AJE (2021) Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol 20(3):203–212PubMed

go back to reference Jabbari E, Duff KE (2021) Tau-targeting antibody therapies: too late, wrong epitope or wrong target? Nat Med 27(8):1341–1342PubMed Jabbari E, Duff KE (2021) Tau-targeting antibody therapies: too late, wrong epitope or wrong target? Nat Med 27(8):1341–1342PubMed

go back to reference Jabbari E, Zetterberg H, Morris HR (2017) Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J Neurol Neurosurg Psychiatry 88(10):883–888PubMed Jabbari E, Zetterberg H, Morris HR (2017) Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J Neurol Neurosurg Psychiatry 88(10):883–888PubMed

go back to reference Jan A, Gonçalves NP, Vaegter CB, Jensen PH, Ferreira N (2021) The prion-like spreading of alpha-synuclein in Parkinson’s disease: update on models and hypotheses. Int J Mol Sci 22(15):8338PubMedPubMedCentral Jan A, Gonçalves NP, Vaegter CB, Jensen PH, Ferreira N (2021) The prion-like spreading of alpha-synuclein in Parkinson’s disease: update on models and hypotheses. Int J Mol Sci 22(15):8338PubMedPubMedCentral

go back to reference Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40(10):1529–1534PubMed Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40(10):1529–1534PubMed

go back to reference Jensen I, Bretschneider A, Stiel S, Wegner F, Höglinger GU, Klietz M (2022) Analysis of Parkinson’s disease outpatient counselling for advance directive creation: a cross-sectional questionnaire-based survey of german general practitioners and neurologists. Brain Sci 12:749PubMedPubMedCentral Jensen I, Bretschneider A, Stiel S, Wegner F, Höglinger GU, Klietz M (2022) Analysis of Parkinson’s disease outpatient counselling for advance directive creation: a cross-sectional questionnaire-based survey of german general practitioners and neurologists. Brain Sci 12:749PubMedPubMedCentral

go back to reference Jensen I, Lescher E, Stiel S, Wegner F, Höglinger G, Klietz M (2021) Analysis of transition of patients with Parkinson’s disease into institutional care: a retrospective pilot study. Brain Sci 11(11):1470PubMedPubMedCentral Jensen I, Lescher E, Stiel S, Wegner F, Höglinger G, Klietz M (2021) Analysis of transition of patients with Parkinson’s disease into institutional care: a retrospective pilot study. Brain Sci 11(11):1470PubMedPubMedCentral

go back to reference Jiang C, Hopfner F, Berg D, Hu MT, Pilotto A, Borroni B, Davis JJ, Tofaris GK (2021) Validation of α-Synuclein in L1CAM-immunocaptured exosomes as a biomarker for the stratification of Parkinsonian syndromes. Movement Disord 36(11):2663–2669PubMed Jiang C, Hopfner F, Berg D, Hu MT, Pilotto A, Borroni B, Davis JJ, Tofaris GK (2021) Validation of α-Synuclein in L1CAM-immunocaptured exosomes as a biomarker for the stratification of Parkinsonian syndromes. Movement Disord 36(11):2663–2669PubMed

go back to reference Jiang C, Hopfner F, Katsikoudi A, Hein R, Catli C, Evetts S, Huang Y, Wang H, Ryder JW, Kuhlenbaeumer G, Deuschl G, Padovani A, Berg D, Borroni B, Hu MT, Davis JJ, Tofaris GK (2020) Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry 91(7):720–729PubMed Jiang C, Hopfner F, Katsikoudi A, Hein R, Catli C, Evetts S, Huang Y, Wang H, Ryder JW, Kuhlenbaeumer G, Deuschl G, Padovani A, Berg D, Borroni B, Hu MT, Davis JJ, Tofaris GK (2020) Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry 91(7):720–729PubMed

go back to reference Johnston HE, Samant RS (2021) Alternative systems for misfolded protein clearance: life beyond the proteasome. FEBS J 288(15):4464–4487PubMed Johnston HE, Samant RS (2021) Alternative systems for misfolded protein clearance: life beyond the proteasome. FEBS J 288(15):4464–4487PubMed

go back to reference Jucker M, Walker LC (2018) Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci 21(10):1341–1349PubMedPubMedCentral Jucker M, Walker LC (2018) Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci 21(10):1341–1349PubMedPubMedCentral

go back to reference Kang J-H, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM (2013) Association of cerebrospinal fluid β-amyloid 1–42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70(10):1277–1287PubMedPubMedCentral Kang J-H, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM (2013) Association of cerebrospinal fluid β-amyloid 1–42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70(10):1277–1287PubMedPubMedCentral

go back to reference Klietz M, Berndt JM, Wegner F, Schneider N, Höglinger GU, Eggers C, Stiel S (2020a) Consensus-based recommendations for advance directives of people with Parkinson’s Disease in regard to typical complications by German movement disorder specialists. J Clin Med 9(2):449PubMedCentral Klietz M, Berndt JM, Wegner F, Schneider N, Höglinger GU, Eggers C, Stiel S (2020a) Consensus-based recommendations for advance directives of people with Parkinson’s Disease in regard to typical complications by German movement disorder specialists. J Clin Med 9(2):449PubMedCentral

go back to reference Klietz M, Bronzlik P, Nösel P, Wegner F, Dressler DW, Dadak M, Maudsley AA, Sheriff S, Lanfermann H, Ding X-Q (2019a) Altered neurometabolic profile in early Parkinson’s disease: a study with short echo-time whole brain MR spectroscopic imaging. Front Neurol 10:777PubMedPubMedCentral Klietz M, Bronzlik P, Nösel P, Wegner F, Dressler DW, Dadak M, Maudsley AA, Sheriff S, Lanfermann H, Ding X-Q (2019a) Altered neurometabolic profile in early Parkinson’s disease: a study with short echo-time whole brain MR spectroscopic imaging. Front Neurol 10:777PubMedPubMedCentral

go back to reference Klietz M, Eichel HV, Staege S, Kutschenko A, Respondek G, Huber MK, Greten S, Höglinger GU, Wegner F (2021a) Validation of the Parkinson’s disease caregiver burden questionnaire in progressive supranuclear palsy. Parkinson’s Dis 2021:9990679 Klietz M, Eichel HV, Staege S, Kutschenko A, Respondek G, Huber MK, Greten S, Höglinger GU, Wegner F (2021a) Validation of the Parkinson’s disease caregiver burden questionnaire in progressive supranuclear palsy. Parkinson’s Dis 2021:9990679

go back to reference Klietz M, von Eichel H, Schnur T, Staege S, Höglinger GU, Wegner F, Stiel S (2021b) One year trajectory of caregiver burden in Parkinson’s disease and analysis of gender-specific aspects. Brain Sci 11(3):295PubMedPubMedCentral Klietz M, von Eichel H, Schnur T, Staege S, Höglinger GU, Wegner F, Stiel S (2021b) One year trajectory of caregiver burden in Parkinson’s disease and analysis of gender-specific aspects. Brain Sci 11(3):295PubMedPubMedCentral

go back to reference Klietz M, Elaman MH, Mahmoudi N, Nösel P, Ahlswede M, Wegner F, Höglinger GU, Lanfermann H, Ding X-Q (2021c) Cerebral microstructural alterations in patients with early Parkinson’s disease detected with quantitative magnetic resonance measurements. Front Aging Neurosci 13:763331PubMedPubMedCentral Klietz M, Elaman MH, Mahmoudi N, Nösel P, Ahlswede M, Wegner F, Höglinger GU, Lanfermann H, Ding X-Q (2021c) Cerebral microstructural alterations in patients with early Parkinson’s disease detected with quantitative magnetic resonance measurements. Front Aging Neurosci 13:763331PubMedPubMedCentral

go back to reference Klietz M, Greten S, Wegner F, Höglinger GU (2019b) Safety and tolerability of pharmacotherapies for Parkinson’s disease in geriatric patients. Drugs Aging 36(6):511–530PubMed Klietz M, Greten S, Wegner F, Höglinger GU (2019b) Safety and tolerability of pharmacotherapies for Parkinson’s disease in geriatric patients. Drugs Aging 36(6):511–530PubMed

go back to reference Klietz M, Öcalan Ö, Schneider N, Dressler D, Stiel S, Wegner F (2019c) Advance directives of german people with Parkinson’s disease are unspecific in regard to typical complications. Parkinson’s Dis 2019:2107821 Klietz M, Öcalan Ö, Schneider N, Dressler D, Stiel S, Wegner F (2019c) Advance directives of german people with Parkinson’s disease are unspecific in regard to typical complications. Parkinson’s Dis 2019:2107821

go back to reference Klietz M, Rippena L, Lange F, Tulke A, Paracka L, Dressler D, Wegner F (2019d) Validating the Parkinson’s disease caregiver burden questionnaire (PDCB) in German caregivers of advanced Parkinson’s disease patients. Int Psychogeriatr 31(12):1791–1800PubMed Klietz M, Rippena L, Lange F, Tulke A, Paracka L, Dressler D, Wegner F (2019d) Validating the Parkinson’s disease caregiver burden questionnaire (PDCB) in German caregivers of advanced Parkinson’s disease patients. Int Psychogeriatr 31(12):1791–1800PubMed

go back to reference Klietz M, Schnur T, Drexel S, Lange F, Tulke A, Rippena L, Paracka L, Dressler D, Höglinger GU, Wegner F (2020b) Association of motor and cognitive symptoms with health-related quality of life and caregiver burden in a German cohort of advanced Parkinson’s disease patients. Parkinson’s Dis 2020:5184084 Klietz M, Schnur T, Drexel S, Lange F, Tulke A, Rippena L, Paracka L, Dressler D, Höglinger GU, Wegner F (2020b) Association of motor and cognitive symptoms with health-related quality of life and caregiver burden in a German cohort of advanced Parkinson’s disease patients. Parkinson’s Dis 2020:5184084

go back to reference Klietz M, Schnur T, Drexel SC, Lange F, Paracka L, Huber MK, Dressler D, Höglinger GU, Wegner F (2020c) Alexithymia is associated with reduced quality of life and increased caregiver burden in Parkinson’s disease. Brain Sci 10(6):401PubMedCentral Klietz M, Schnur T, Drexel SC, Lange F, Paracka L, Huber MK, Dressler D, Höglinger GU, Wegner F (2020c) Alexithymia is associated with reduced quality of life and increased caregiver burden in Parkinson’s disease. Brain Sci 10(6):401PubMedCentral

go back to reference Klietz M, Tulke A, Müschen LH, Paracka L, Schrader C, Dressler DW, Wegner F (2018) Impaired quality of life and need for palliative care in a German cohort of advanced Parkinson’s disease patients. Front Neurol 9:120PubMedPubMedCentral Klietz M, Tulke A, Müschen LH, Paracka L, Schrader C, Dressler DW, Wegner F (2018) Impaired quality of life and need for palliative care in a German cohort of advanced Parkinson’s disease patients. Front Neurol 9:120PubMedPubMedCentral

go back to reference Koga S, Dickson DW (2018) Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy. J Neurol Neurosurg Psychiatry 89(2):175–184PubMed Koga S, Dickson DW (2018) Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy. J Neurol Neurosurg Psychiatry 89(2):175–184PubMed

go back to reference Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW (2021) Neuropathology and molecular diagnosis of Synucleinopathies. Mol Neurodegener 16(1):83PubMedPubMedCentral Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW (2021) Neuropathology and molecular diagnosis of Synucleinopathies. Mol Neurodegener 16(1):83PubMedPubMedCentral

go back to reference Korat Š, Bidesi NSR, Bonanno F, Di Nanni A, Hoàng ANN, Herfert K, Maurer A, Battisti UM, Bowden GD, Thonon D, Vugts D, Windhorst AD, Herth MM (2021) Alpha-synuclein PET tracer development-an overview about current efforts. Pharmaceuticals (basel, Switzerland) 14(9):847 Korat Š, Bidesi NSR, Bonanno F, Di Nanni A, Hoàng ANN, Herfert K, Maurer A, Battisti UM, Bowden GD, Thonon D, Vugts D, Windhorst AD, Herth MM (2021) Alpha-synuclein PET tracer development-an overview about current efforts. Pharmaceuticals (basel, Switzerland) 14(9):847

go back to reference Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, Coughlin D, Giese A, Grossman M, Kurz C, McMillan CT, Gelpi E, Compta Y, van Swieten JC, Laat LD, Troakes C, Al-Sarraj S, Robinson JL, Roeber S, Xie SX, Lee VM-Y, Trojanowski JQ, Höglinger GU (2020) Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol 140(2):99–119PubMedPubMedCentral Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, Coughlin D, Giese A, Grossman M, Kurz C, McMillan CT, Gelpi E, Compta Y, van Swieten JC, Laat LD, Troakes C, Al-Sarraj S, Robinson JL, Roeber S, Xie SX, Lee VM-Y, Trojanowski JQ, Höglinger GU (2020) Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol 140(2):99–119PubMedPubMedCentral

go back to reference Krey L, Lange P, Tran AT, Greten S, Höglinger GU, Wegner F, Krause O, Klietz M (2021) Patient safety in a box: implementation and evaluation of the emergency box in geriatric and Parkinson patients. J Clin Med 10(23):5618PubMedPubMedCentral Krey L, Lange P, Tran AT, Greten S, Höglinger GU, Wegner F, Krause O, Klietz M (2021) Patient safety in a box: implementation and evaluation of the emergency box in geriatric and Parkinson patients. J Clin Med 10(23):5618PubMedPubMedCentral

go back to reference Kwasny MJ, Oleske DM, Zamudio J, Diegidio R, Höglinger GU (2021) Clinical features observed in general practice associated with the subsequent diagnosis of progressive supranuclear palsy. Front Neurol 12:637176PubMedPubMedCentral Kwasny MJ, Oleske DM, Zamudio J, Diegidio R, Höglinger GU (2021) Clinical features observed in general practice associated with the subsequent diagnosis of progressive supranuclear palsy. Front Neurol 12:637176PubMedPubMedCentral

go back to reference Kwon EH, Tennagels S, Gold R, Gerwert K, Beyer L, Tönges L (2022) Update on CSF biomarkers in Parkinson’s disease. Biomolecules 12(2):329PubMedPubMedCentral Kwon EH, Tennagels S, Gold R, Gerwert K, Beyer L, Tönges L (2022) Update on CSF biomarkers in Parkinson’s disease. Biomolecules 12(2):329PubMedPubMedCentral

go back to reference Lemos M, Venezia S, Refolo V, Heras-Garvin A, Schmidhuber S, Giese A, Leonov A, Ryazanov S, Griesinger C, Galabova G, Staffler G, Wenning GK, Stefanova N (2020) Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance. Transl Neurodegeneration 9(1):38 Lemos M, Venezia S, Refolo V, Heras-Garvin A, Schmidhuber S, Giese A, Leonov A, Ryazanov S, Griesinger C, Galabova G, Staffler G, Wenning GK, Stefanova N (2020) Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance. Transl Neurodegeneration 9(1):38

go back to reference Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU (2016a) The Differential diagnosis and treatment of atypical Parkinsonism. Deutsches Arzteblatt Int 113(5):61–69 Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU (2016a) The Differential diagnosis and treatment of atypical Parkinsonism. Deutsches Arzteblatt Int 113(5):61–69

go back to reference Levin J, Maaß S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, Südmeyer M, Eggert K, Mollenhauer B, Lipp A, Löhle M, Classen J, Münchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, Bötzel K, Ertl-Wagner B, Huppertz H-J, Ricard I, Höglinger GU, André E, Blankenstein C, Canelo M, Düring M, Ebentheuer J, Fricke C, Gerbes A, Groiss S, Gruber D, Hartmann C, Kirchner T, Kroneberg D, Kunz M, Lorenzl S, Moldovan A, Noda A, Pape H, Respondek G, Schäffer E, Schneider M, Schnitzler A, Schulz-Schaeffer W, Schwarz J, Skowronek C, Storch A, Tadic V, Vadász D, Zimmermann B (2019) Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 18(8):724–735PubMed Levin J, Maaß S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, Südmeyer M, Eggert K, Mollenhauer B, Lipp A, Löhle M, Classen J, Münchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, Bötzel K, Ertl-Wagner B, Huppertz H-J, Ricard I, Höglinger GU, André E, Blankenstein C, Canelo M, Düring M, Ebentheuer J, Fricke C, Gerbes A, Groiss S, Gruber D, Hartmann C, Kirchner T, Kroneberg D, Kunz M, Lorenzl S, Moldovan A, Noda A, Pape H, Respondek G, Schäffer E, Schneider M, Schnitzler A, Schulz-Schaeffer W, Schwarz J, Skowronek C, Storch A, Tadic V, Vadász D, Zimmermann B (2019) Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 18(8):724–735PubMed

go back to reference Levin J, Maaß S, Schuberth M, Respondek G, Paul F, Mansmann U, Oertel WH, Lorenzl S, Krismer F, Seppi K, Poewe W, Wenning G, Giese A, Bötzel K, Höglinger G (2016b) The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. J Neural Transmission (vienna, Austria: 1996) 123(4):439–445 Levin J, Maaß S, Schuberth M, Respondek G, Paul F, Mansmann U, Oertel WH, Lorenzl S, Krismer F, Seppi K, Poewe W, Wenning G, Giese A, Bötzel K, Höglinger G (2016b) The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. J Neural Transmission (vienna, Austria: 1996) 123(4):439–445

go back to reference Levin J, Schmidt F, Boehm C, Prix C, Bötzel K, Ryazanov S, Leonov A, Griesinger C, Giese A (2014) The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol 127(5):779–780PubMedPubMedCentral Levin J, Schmidt F, Boehm C, Prix C, Bötzel K, Ryazanov S, Leonov A, Griesinger C, Giese A (2014) The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol 127(5):779–780PubMedPubMedCentral

go back to reference Lingor P, Csoti I, Koschel J, Schrader C, Winkler C, Wolz M, Reichmann H (2016) Der geriatrische Parkinson-Patient - eine neurologische Herausforderung (The Geriatric Patient with Parkinson’s Disease - a Neurological Challenge). Fortschr Neurol Psychiatr 84(Suppl 1):S41–S47PubMed Lingor P, Csoti I, Koschel J, Schrader C, Winkler C, Wolz M, Reichmann H (2016) Der geriatrische Parkinson-Patient - eine neurologische Herausforderung (The Geriatric Patient with Parkinson’s Disease - a Neurological Challenge). Fortschr Neurol Psychiatr 84(Suppl 1):S41–S47PubMed

go back to reference Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1–9PubMed Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1–9PubMed

go back to reference Lopez G, Bayulkem K, Hallett M (2016) Progressive supranuclear palsy (PSP): Richardson syndrome and other PSP variants. Acta Neurol Scand 134(4):242–249PubMedPubMedCentral Lopez G, Bayulkem K, Hallett M (2016) Progressive supranuclear palsy (PSP): Richardson syndrome and other PSP variants. Acta Neurol Scand 134(4):242–249PubMedPubMedCentral

go back to reference Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, Tanner CM, Gilman S, Marshall FJ, Wooten F, Racette B, Chelimsky T, Singer W, Sletten DM, Sandroni P, Mandrekar J (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14(7):710–719PubMedPubMedCentral Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, Tanner CM, Gilman S, Marshall FJ, Wooten F, Racette B, Chelimsky T, Singer W, Sletten DM, Sandroni P, Mandrekar J (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14(7):710–719PubMedPubMedCentral

go back to reference Lum HD, Jordan SR, Brungardt A, Ayele R, Katz M, Miyasaki JM, Hall A, Jones J, Kluger B (2019) Framing advance care planning in Parkinson disease: patient and care partner perspectives. Neurology 92(22):e2571–e2579PubMedPubMedCentral Lum HD, Jordan SR, Brungardt A, Ayele R, Katz M, Miyasaki JM, Hall A, Jones J, Kluger B (2019) Framing advance care planning in Parkinson disease: patient and care partner perspectives. Neurology 92(22):e2571–e2579PubMedPubMedCentral

go back to reference Macleod AD, Taylor KSM, Counsell CE (2014) Mortality in Parkinson’s disease: a systematic review and meta-analysis. Movement Disord 29(13):1615–1622PubMed Macleod AD, Taylor KSM, Counsell CE (2014) Mortality in Parkinson’s disease: a systematic review and meta-analysis. Movement Disord 29(13):1615–1622PubMed

go back to reference Magistrelli L, Contaldi E, Comi C (2021) The Impact of SNCA variations and its product alpha-synuclein on non-motor features of Parkinson’s disease. Life (Basel, Switzerland) 11(8):804 Magistrelli L, Contaldi E, Comi C (2021) The Impact of SNCA variations and its product alpha-synuclein on non-motor features of Parkinson’s disease. Life (Basel, Switzerland) 11(8):804

go back to reference Mahlknecht P, Hotter A, Hussl A, Esterhammer R, Schocke M, Seppi K (2010) Significance of MRI in diagnosis and differential diagnosis of Parkinson’s disease. Neurodegener Dis 7(5):300–318PubMed Mahlknecht P, Hotter A, Hussl A, Esterhammer R, Schocke M, Seppi K (2010) Significance of MRI in diagnosis and differential diagnosis of Parkinson’s disease. Neurodegener Dis 7(5):300–318PubMed

go back to reference Mao X, Ou MT, Karuppagounder SS, Kam T-I, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin J-H, Kang HC, Zhang J, Xu J, Chen R, Park H, Andrabi SA, Kang SU, Gonçalves RA, Liang Y, Zhang S, Qi C, Lam S, Keiler JA, Tyson J, Kim D, Panicker N, Yun SP, Workman CJ, Vignali DAA, Dawson VL, Ko HS, Dawson TM (2016) Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science (new York, NY) 353(6307):3374 Mao X, Ou MT, Karuppagounder SS, Kam T-I, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin J-H, Kang HC, Zhang J, Xu J, Chen R, Park H, Andrabi SA, Kang SU, Gonçalves RA, Liang Y, Zhang S, Qi C, Lam S, Keiler JA, Tyson J, Kim D, Panicker N, Yun SP, Workman CJ, Vignali DAA, Dawson VL, Ko HS, Dawson TM (2016) Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science (new York, NY) 353(6307):3374

go back to reference Marras C, Chaudhuri KR, Titova N, Mestre TA (2020) Therapy of Parkinson’s disease subtypes. Neurotherapeutics 17(4):1366–1377PubMedPubMedCentral Marras C, Chaudhuri KR, Titova N, Mestre TA (2020) Therapy of Parkinson’s disease subtypes. Neurotherapeutics 17(4):1366–1377PubMedPubMedCentral

go back to reference Martinez-Martin P, Macaulay D, Jalundhwala YJ, Mu F, Ohashi E, Marshall T, Sail K (2019) The long-term direct and indirect economic burden among Parkinson’s disease caregivers in the United States. Movement Disord 34(2):236–245PubMed Martinez-Martin P, Macaulay D, Jalundhwala YJ, Mu F, Ohashi E, Marshall T, Sail K (2019) The long-term direct and indirect economic burden among Parkinson’s disease caregivers in the United States. Movement Disord 34(2):236–245PubMed

go back to reference Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, Agüera-Ortiz L, Weintraub D, Riesco A, Kurtis MM, Chaudhuri KR (2015) Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease. Parkinsonism Relat Disord 21(6):629–634PubMed Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, Agüera-Ortiz L, Weintraub D, Riesco A, Kurtis MM, Chaudhuri KR (2015) Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease. Parkinsonism Relat Disord 21(6):629–634PubMed

go back to reference Martinez-Valbuena I, Visanji NP, Olszewska DA, Sousa M, Bhakta P, Vasilevskaya A, Anastassiadis C, Tartaglia MC, Kovacs GG, Lang AE (2022) Combining Skin α-synuclein real-time quaking-induced conversion and circulating neurofilament light chain to distinguish multiple system atrophy and Parkinson’s disease. Mov Disord 37(3):648–650PubMed Martinez-Valbuena I, Visanji NP, Olszewska DA, Sousa M, Bhakta P, Vasilevskaya A, Anastassiadis C, Tartaglia MC, Kovacs GG, Lang AE (2022) Combining Skin α-synuclein real-time quaking-induced conversion and circulating neurofilament light chain to distinguish multiple system atrophy and Parkinson’s disease. Mov Disord 37(3):648–650PubMed

go back to reference Meinders MJ, Gentile G, Schrag AE, Konitsiotis S, Eggers C, Taba P, Lorenzl S, Odin P, Rosqvist K, Chaudhuri KR, Antonini A, Bloem BR, Groot MM (2021) Advance care planning and care coordination for people with Parkinson’s disease and their family caregivers-study protocol for a multicentre, randomized controlled trial. Front Neurol 12:673893PubMedPubMedCentral Meinders MJ, Gentile G, Schrag AE, Konitsiotis S, Eggers C, Taba P, Lorenzl S, Odin P, Rosqvist K, Chaudhuri KR, Antonini A, Bloem BR, Groot MM (2021) Advance care planning and care coordination for people with Parkinson’s disease and their family caregivers-study protocol for a multicentre, randomized controlled trial. Front Neurol 12:673893PubMedPubMedCentral

go back to reference Mestre TA, Fereshtehnejad S-M, Berg D, Bohnen NI, Dujardin K, Erro R, Espay AJ, Halliday G, van Hilten JJ, Hu MT, Jeon B, Klein C, Leentjens AFG, Marinus J, Mollenhauer B, Postuma R, Rajalingam R, Rodríguez-Violante M, Simuni T, Surmeier DJ, Weintraub D, McDermott MP, Lawton M, Marras C (2021) Parkinson’s disease subtypes: critical appraisal and recommendations. J Parkinsons Dis 11(2):395–404PubMedPubMedCentral Mestre TA, Fereshtehnejad S-M, Berg D, Bohnen NI, Dujardin K, Erro R, Espay AJ, Halliday G, van Hilten JJ, Hu MT, Jeon B, Klein C, Leentjens AFG, Marinus J, Mollenhauer B, Postuma R, Rajalingam R, Rodríguez-Violante M, Simuni T, Surmeier DJ, Weintraub D, McDermott MP, Lawton M, Marras C (2021) Parkinson’s disease subtypes: critical appraisal and recommendations. J Parkinsons Dis 11(2):395–404PubMedPubMedCentral

go back to reference Miglis MG, Adler CH, Antelmi E, Arnaldi D, Baldelli L, Boeve BF, Cesari M, Dall’Antonia I, Diederich NJ, Doppler K, Dušek P, Ferri R, Gagnon J-F, Gan-Or Z, Hermann W, Högl B, Hu MT, Iranzo A, Janzen A, Kuzkina A, Lee J-Y, Leenders KL, Lewis SJG, Liguori C, Liu J, Lo C, Ehgoetz Martens KA, Nepozitek J, Plazzi G, Provini F, Puligheddu M, Rolinski M, Rusz J, Stefani A, Summers RLS, Yoo D, Zitser J, Oertel WH (2021) Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol 20(8):671–684PubMedPubMedCentral Miglis MG, Adler CH, Antelmi E, Arnaldi D, Baldelli L, Boeve BF, Cesari M, Dall’Antonia I, Diederich NJ, Doppler K, Dušek P, Ferri R, Gagnon J-F, Gan-Or Z, Hermann W, Högl B, Hu MT, Iranzo A, Janzen A, Kuzkina A, Lee J-Y, Leenders KL, Lewis SJG, Liguori C, Liu J, Lo C, Ehgoetz Martens KA, Nepozitek J, Plazzi G, Provini F, Puligheddu M, Rolinski M, Rusz J, Stefani A, Summers RLS, Yoo D, Zitser J, Oertel WH (2021) Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol 20(8):671–684PubMedPubMedCentral

go back to reference Miyasaki JM (2013) Palliative care in Parkinson’s disease. Curr Neurol Neurosci Rep 13(8):367PubMed Miyasaki JM (2013) Palliative care in Parkinson’s disease. Curr Neurol Neurosci Rep 13(8):367PubMed

go back to reference Miyasaki JM, Kluger B (2015) Palliative care for Parkinson’s disease: has the time come? Curr Neurol Neurosci Rep 15(5):26PubMed Miyasaki JM, Kluger B (2015) Palliative care for Parkinson’s disease: has the time come? Curr Neurol Neurosci Rep 15(5):26PubMed

go back to reference Miyasaki JM, Lim S-Y, Chaudhuri KR, Antonini A, Piemonte M, Richfield E, Alburquerque Gonzalez D, Lorenzl S, Walker R, Bhidayasiri R, Bouca R, McConvey V (2022) Access and attitudes toward palliative care among movement disorders clinicians. Movement Disord 37(1):182–189PubMed Miyasaki JM, Lim S-Y, Chaudhuri KR, Antonini A, Piemonte M, Richfield E, Alburquerque Gonzalez D, Lorenzl S, Walker R, Bhidayasiri R, Bouca R, McConvey V (2022) Access and attitudes toward palliative care among movement disorders clinicians. Movement Disord 37(1):182–189PubMed

go back to reference Mosley PE, Moodie R, Dissanayaka N (2017) Caregiver burden in Parkinson disease: a critical review of recent literature. J Geriatr Psychiatry Neurol 30(5):235–252PubMed Mosley PE, Moodie R, Dissanayaka N (2017) Caregiver burden in Parkinson disease: a critical review of recent literature. J Geriatr Psychiatry Neurol 30(5):235–252PubMed

go back to reference Moßhammer D, Haumann H, Mörike K, Joos S (2016) Polypharmacy-an upward trend with unpredictable effects. Deutsches Arzteblatt Int 113(38):627–633 Moßhammer D, Haumann H, Mörike K, Joos S (2016) Polypharmacy-an upward trend with unpredictable effects. Deutsches Arzteblatt Int 113(38):627–633

go back to reference Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, Bras J, Young E, von Coelln R, Simón-Sánchez J, Schulte C, Sharma M, Krohn L, Pihlstrøm L, Siitonen A, Iwaki H, Leonard H, Faghri F, Gibbs JR, Hernandez DG, Scholz SW, Botia JA, Martinez M, Corvol J-C, Lesage S, Jankovic J, Shulman LM, Sutherland M, Tienari P, Majamaa K, Toft M, Andreassen OA, Bangale T, Brice A, Yang J, Gan-Or Z, Gasser T, Heutink P, Shulman JM, Wood NW, Hinds DA, Hardy JA, Morris HR, Gratten J, Visscher PM, Graham RR, Singleton AB, Adarmes-Gómez AD, Aguilar M, Aitkulova A, Akhmetzhanov V, Alcalay RN, Alvarez I, Alvarez V, Barrero FJ, Bergareche Yarza JA, Bernal-Bernal I, Billingsley K, Blazquez M, Bonilla-Toribio M, Botía JA, Boungiorno MT, Brockmann K, Bubb V, Buiza-Rueda D, Cámara A, Carrillo F, Carrión-Claro M, Cerdan D, Chelban V, Clarimón J, Clarke C, Compta Y, Cookson MR, Craig DW, Danjou F, Diez-Fairen M, Dols-Icardo O, Duarte J, Duran R, Escamilla-Sevilla F, Escott-Price V, Ezquerra M, Feliz C, Fernández M, Fernández-Santiago R, Finkbeiner S, Foltynie T, Garcia C, García-Ruiz P, Gomez Heredia MJ, Gómez-Garre P, González MM, Gonzalez-Aramburu I, Guelfi S, Guerreiro R, Hardy J, Hassin-Baer S, Hoenicka J, Holmans P, Houlden H, Infante J, Jesús S, Jimenez-Escrig A, Kaishybayeva G, Kaiyrzhanov R, Karimova A, Kinghorn KJ, Koks S, Kulisevsky J, Labrador-Espinosa MA, Leonard HL, Lewis P, Lopez-Sendon JL, Lovering R, Lubbe S, Lungu C, Macias D, Manzoni C, Marín J, Marinus J, Marti MJ, Martínez Torres I, Martínez-Castrillo JC, Mata M, Mencacci NE, Méndez-del-Barrio C, Middlehurst B, Mínguez A, Mir P, Mok KY, Muñoz E, Narendra D, Ojo OO, Okubadejo NU, Pagola AG, Pastor P, Perez Errazquin F, Periñán-Tocino T, Pihlstrom L, Plun-Favreau H, Quinn J, R’Bibo L, Reed X, Rezola EM, Rizig M, Rizzu P, Robak L, Rodriguez AS, Rouleau GA, Ruiz-Martínez J, Ruz C, Ryten M, Sadykova D, Schreglmann S, Shashkin C, Sierra M, Suarez-Sanmartin E, Taba P, Tabernero C, Tan MX, Tartari JP, Tejera-Parrado C, Tolosa E, Trabzuni D, Valldeoriola F, van Hilten JJ, van Keuren-Jensen K, Vargas-González L, Vela L, Vives F, Williams N, Zharkinbekova N, Zharmukhanov Z, Zholdybayeva E, Zimprich A, Ylikotila P, Reich S, Savitt J, Agee M, Alipanahi B, Auton A, Bell RK, Bryc K, Elson SL, Fontanillas P, Furlotte NA, Huber KE, Hicks B, Jewett EM, Jiang Y, Kleinman A, Lin K-H, Litterman NK, McCreight JC, McIntyre MH, McManus KF, Mountain JL, Noblin ES, Northover CA, Pitts SJ, Poznik GD, Sathirapongsasuti JF, Shelton JF, Shringarpure S, Tian C, Tung J, Vacic V, Wang X, Wilson CH, Anderson T, Bentley S, Dalrymple-Alford J, Fowdar J, Halliday G, Henders AK, Hickie I, Kassam I, Kennedy M, Kwok J, Lewis S, Mellick G, Montgomery G, Pearson J, Pitcher T, Sidorenko J, Silburn PA, Wallace L, Wray NR, Zhang F (2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 18(12):1091–1102PubMedPubMedCentral Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, Bras J, Young E, von Coelln R, Simón-Sánchez J, Schulte C, Sharma M, Krohn L, Pihlstrøm L, Siitonen A, Iwaki H, Leonard H, Faghri F, Gibbs JR, Hernandez DG, Scholz SW, Botia JA, Martinez M, Corvol J-C, Lesage S, Jankovic J, Shulman LM, Sutherland M, Tienari P, Majamaa K, Toft M, Andreassen OA, Bangale T, Brice A, Yang J, Gan-Or Z, Gasser T, Heutink P, Shulman JM, Wood NW, Hinds DA, Hardy JA, Morris HR, Gratten J, Visscher PM, Graham RR, Singleton AB, Adarmes-Gómez AD, Aguilar M, Aitkulova A, Akhmetzhanov V, Alcalay RN, Alvarez I, Alvarez V, Barrero FJ, Bergareche Yarza JA, Bernal-Bernal I, Billingsley K, Blazquez M, Bonilla-Toribio M, Botía JA, Boungiorno MT, Brockmann K, Bubb V, Buiza-Rueda D, Cámara A, Carrillo F, Carrión-Claro M, Cerdan D, Chelban V, Clarimón J, Clarke C, Compta Y, Cookson MR, Craig DW, Danjou F, Diez-Fairen M, Dols-Icardo O, Duarte J, Duran R, Escamilla-Sevilla F, Escott-Price V, Ezquerra M, Feliz C, Fernández M, Fernández-Santiago R, Finkbeiner S, Foltynie T, Garcia C, García-Ruiz P, Gomez Heredia MJ, Gómez-Garre P, González MM, Gonzalez-Aramburu I, Guelfi S, Guerreiro R, Hardy J, Hassin-Baer S, Hoenicka J, Holmans P, Houlden H, Infante J, Jesús S, Jimenez-Escrig A, Kaishybayeva G, Kaiyrzhanov R, Karimova A, Kinghorn KJ, Koks S, Kulisevsky J, Labrador-Espinosa MA, Leonard HL, Lewis P, Lopez-Sendon JL, Lovering R, Lubbe S, Lungu C, Macias D, Manzoni C, Marín J, Marinus J, Marti MJ, Martínez Torres I, Martínez-Castrillo JC, Mata M, Mencacci NE, Méndez-del-Barrio C, Middlehurst B, Mínguez A, Mir P, Mok KY, Muñoz E, Narendra D, Ojo OO, Okubadejo NU, Pagola AG, Pastor P, Perez Errazquin F, Periñán-Tocino T, Pihlstrom L, Plun-Favreau H, Quinn J, R’Bibo L, Reed X, Rezola EM, Rizig M, Rizzu P, Robak L, Rodriguez AS, Rouleau GA, Ruiz-Martínez J, Ruz C, Ryten M, Sadykova D, Schreglmann S, Shashkin C, Sierra M, Suarez-Sanmartin E, Taba P, Tabernero C, Tan MX, Tartari JP, Tejera-Parrado C, Tolosa E, Trabzuni D, Valldeoriola F, van Hilten JJ, van Keuren-Jensen K, Vargas-González L, Vela L, Vives F, Williams N, Zharkinbekova N, Zharmukhanov Z, Zholdybayeva E, Zimprich A, Ylikotila P, Reich S, Savitt J, Agee M, Alipanahi B, Auton A, Bell RK, Bryc K, Elson SL, Fontanillas P, Furlotte NA, Huber KE, Hicks B, Jewett EM, Jiang Y, Kleinman A, Lin K-H, Litterman NK, McCreight JC, McIntyre MH, McManus KF, Mountain JL, Noblin ES, Northover CA, Pitts SJ, Poznik GD, Sathirapongsasuti JF, Shelton JF, Shringarpure S, Tian C, Tung J, Vacic V, Wang X, Wilson CH, Anderson T, Bentley S, Dalrymple-Alford J, Fowdar J, Halliday G, Henders AK, Hickie I, Kassam I, Kennedy M, Kwok J, Lewis S, Mellick G, Montgomery G, Pearson J, Pitcher T, Sidorenko J, Silburn PA, Wallace L, Wray NR, Zhang F (2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 18(12):1091–1102PubMedPubMedCentral

go back to reference Nichols MR, St-Pierre M-K, Wendeln A-C, Makoni NJ, Gouwens LK, Garrad EC, Sohrabi M, Neher JJ, Tremblay M-E, Combs CK (2019) Inflammatory mechanisms in neurodegeneration. J Neurochem 149(5):562–581PubMedPubMedCentral Nichols MR, St-Pierre M-K, Wendeln A-C, Makoni NJ, Gouwens LK, Garrad EC, Sohrabi M, Neher JJ, Tremblay M-E, Combs CK (2019) Inflammatory mechanisms in neurodegeneration. J Neurochem 149(5):562–581PubMedPubMedCentral

go back to reference Niewiadomska G, Niewiadomski W, Steczkowska M, Gasiorowska A (2021) Tau oligomers neurotoxicity. Life (basel, Switzerland) 11(1):28 Niewiadomska G, Niewiadomski W, Steczkowska M, Gasiorowska A (2021) Tau oligomers neurotoxicity. Life (basel, Switzerland) 11(1):28

go back to reference Nuebling GS, Butzhammer E, Lorenzl S (2021) Assisted suicide in Parkinsonian disorders. Front Neurol 12:656599PubMedPubMedCentral Nuebling GS, Butzhammer E, Lorenzl S (2021) Assisted suicide in Parkinsonian disorders. Front Neurol 12:656599PubMedPubMedCentral

go back to reference Okunoye O, Kojima G, Marston L, Walters K, Schrag A (2020) Factors associated with hospitalisation among people with Parkinson’s disease - a systematic review and meta-analysis. Parkinsonism Relat Disord 71:66–72PubMed Okunoye O, Kojima G, Marston L, Walters K, Schrag A (2020) Factors associated with hospitalisation among people with Parkinson’s disease - a systematic review and meta-analysis. Parkinsonism Relat Disord 71:66–72PubMed

go back to reference Oliver D, Borasio GD, Veronese S, Voltz R, Lorenzl S, Hepgul N (2020) Current collaboration between palliative care and neurology: a survey of clinicians in Europe. BMJ Support Palliative Care. https://doi.org/10.1136/bmjspcare-2020-002322CrossRef Oliver D, Borasio GD, Veronese S, Voltz R, Lorenzl S, Hepgul N (2020) Current collaboration between palliative care and neurology: a survey of clinicians in Europe. BMJ Support Palliative Care. https://​doi.​org/​10.​1136/​bmjspcare-2020-002322CrossRef

go back to reference Oliver DJ, Borasio GD, Caraceni A, de Visser M, Grisold W, Lorenzl S, Veronese S, Voltz R (2016) A consensus review on the development of palliative care for patients with chronic and progressive neurological disease. Eur J Neurol 23(1):30–38PubMed Oliver DJ, Borasio GD, Caraceni A, de Visser M, Grisold W, Lorenzl S, Veronese S, Voltz R (2016) A consensus review on the development of palliative care for patients with chronic and progressive neurological disease. Eur J Neurol 23(1):30–38PubMed

go back to reference Osaki Y, Ben-Shlomo Y, Lees AJ, Wenning GK, Quinn NP (2009) A validation exercise on the new consensus criteria for multiple system atrophy. Movement Disord 24(15):2272–2276PubMed Osaki Y, Ben-Shlomo Y, Lees AJ, Wenning GK, Quinn NP (2009) A validation exercise on the new consensus criteria for multiple system atrophy. Movement Disord 24(15):2272–2276PubMed

go back to reference Owens E, Josephs KA, Savica R, Hassan A, Klassen B, Bower J, Maraganore D, Matsumoto J, Ahlskog JE (2016) The clinical spectrum and natural history of pure akinesia with gait freezing. J Neurol 263(12):2419–2423PubMed Owens E, Josephs KA, Savica R, Hassan A, Klassen B, Bower J, Maraganore D, Matsumoto J, Ahlskog JE (2016) The clinical spectrum and natural history of pure akinesia with gait freezing. J Neurol 263(12):2419–2423PubMed

go back to reference de Pablo-Fernández E, Lees AJ, Holton JL, Warner TT (2019) Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease. JAMA Neurol 76(4):470–479PubMedPubMedCentral de Pablo-Fernández E, Lees AJ, Holton JL, Warner TT (2019) Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease. JAMA Neurol 76(4):470–479PubMedPubMedCentral

go back to reference Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A (2021) A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s Disease (PASADENA): rationale, design, and baseline data. Front Neurol 12:705407PubMedPubMedCentral Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A (2021) A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s Disease (PASADENA): rationale, design, and baseline data. Front Neurol 12:705407PubMedPubMedCentral

go back to reference Pajares M, Rojo I, A, Manda G, Boscá L, Cuadrado A, (2020) Inflammation in Parkinson’s disease: mechanisms and therapeutic implications. Cells 9(7):1687PubMedCentral Pajares M, Rojo I, A, Manda G, Boscá L, Cuadrado A, (2020) Inflammation in Parkinson’s disease: mechanisms and therapeutic implications. Cells 9(7):1687PubMedCentral

go back to reference Palleis C, Brendel M, Finze A, Weidinger E, Bötzel K, Danek A, Beyer L, Nitschmann A, Kern M, Biechele G, Rauchmann B-S, Häckert J, Höllerhage M, Stephens AW, Drzezga A, van Eimeren T, Villemagne VL, Schildan A, Barthel H, Patt M, Sabri O, Bartenstein P, Perneczky R, Haass C, Levin J, Höglinger GU (2021) Cortical 18 FPI-2620 binding differentiates corticobasal syndrome subtypes. Movement Disord 36(9):2104–2115PubMed Palleis C, Brendel M, Finze A, Weidinger E, Bötzel K, Danek A, Beyer L, Nitschmann A, Kern M, Biechele G, Rauchmann B-S, Häckert J, Höllerhage M, Stephens AW, Drzezga A, van Eimeren T, Villemagne VL, Schildan A, Barthel H, Patt M, Sabri O, Bartenstein P, Perneczky R, Haass C, Levin J, Höglinger GU (2021) Cortical 18 FPI-2620 binding differentiates corticobasal syndrome subtypes. Movement Disord 36(9):2104–2115PubMed

go back to reference Palleis C, Morenas-Rodriguez E, Murcia FJM, Giese A, Nuscher B, Haass C, Höglinger G, Bötzel K, Levin J (2020) Longitudinal correlation between neurofilament light chain and UMSARS in multiple system atrophy. Clin Neurol Neurosurg 195:105924PubMed Palleis C, Morenas-Rodriguez E, Murcia FJM, Giese A, Nuscher B, Haass C, Höglinger G, Bötzel K, Levin J (2020) Longitudinal correlation between neurofilament light chain and UMSARS in multiple system atrophy. Clin Neurol Neurosurg 195:105924PubMed

go back to reference Papapetropoulos S, Singer C, McCorquodale D, Gonzalez J, Mash DC (2005) Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP). Parkinsonism Relat Disord 11(7):459–463PubMed Papapetropoulos S, Singer C, McCorquodale D, Gonzalez J, Mash DC (2005) Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP). Parkinsonism Relat Disord 11(7):459–463PubMed

go back to reference Parkinson J (1817; 2002) An essay on the shaking palsy. 1817. J Neuropsychiatr Clin Neurosci 14(2):223–36; discussion 222 Parkinson J (1817; 2002) An essay on the shaking palsy. 1817. J Neuropsychiatr Clin Neurosci 14(2):223–36; discussion 222

go back to reference Peralta C, Strafella AP, van Eimeren T, Ceravolo R, Seppi K, Kaasinen V, Arena JE, Lehericy S (2022) Pragmatic approach on neuroimaging techniques for the differential diagnosis of Parkinsonisms. Movement Disord Clin Pract 9(1):6–19 Peralta C, Strafella AP, van Eimeren T, Ceravolo R, Seppi K, Kaasinen V, Arena JE, Lehericy S (2022) Pragmatic approach on neuroimaging techniques for the differential diagnosis of Parkinsonisms. Movement Disord Clin Pract 9(1):6–19

go back to reference Pereira MF, Buchanan T, Höglinger GU, Bogdanovic M, Tofaris G, Prangnell S, Sarangmat N, FitzGerald JJ, Antoniades CA (2022) Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study. BMJ Neurol Open 4(1):e000214PubMedPubMedCentral Pereira MF, Buchanan T, Höglinger GU, Bogdanovic M, Tofaris G, Prangnell S, Sarangmat N, FitzGerald JJ, Antoniades CA (2022) Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study. BMJ Neurol Open 4(1):e000214PubMedPubMedCentral

go back to reference Pérez-Soriano A, Giraldo DM, Ríos J, Muñoz E, Compta Y, Martí MJ (2021) Progression of motor and non-motor symptoms in multiple system atrophy: a prospective study from the Catalan-MSA registry. J Parkinsons Dis 11(2):685–694PubMed Pérez-Soriano A, Giraldo DM, Ríos J, Muñoz E, Compta Y, Martí MJ (2021) Progression of motor and non-motor symptoms in multiple system atrophy: a prospective study from the Catalan-MSA registry. J Parkinsons Dis 11(2):685–694PubMed

go back to reference Pilotto A, Imarisio A, Conforti F, Scalvini A, Masciocchi S, Nocivelli S, Turrone R, Gipponi S, Cottini E, Borroni B, Rizzetti MC, Pizzi M, Bonanni L, Sturchio A, Espay AJ, Zetterberg H, Ashton NJ, Hye A, Padovani A (2021) Plasma NfL, clinical subtypes and motor progression in Parkinson’s disease. Parkinsonism Relat Disord 87:41–47PubMed Pilotto A, Imarisio A, Conforti F, Scalvini A, Masciocchi S, Nocivelli S, Turrone R, Gipponi S, Cottini E, Borroni B, Rizzetti MC, Pizzi M, Bonanni L, Sturchio A, Espay AJ, Zetterberg H, Ashton NJ, Hye A, Padovani A (2021) Plasma NfL, clinical subtypes and motor progression in Parkinson’s disease. Parkinsonism Relat Disord 87:41–47PubMed

go back to reference Piot I, Schweyer K, Respondek G, Stamelou M, Sckopke P, Schenk T, Goetz CG, Stebbins GT, Höglinger GU (2020) The progressive supranuclear palsy clinical deficits scale. Movement Disord 35(4):650–661PubMed Piot I, Schweyer K, Respondek G, Stamelou M, Sckopke P, Schenk T, Goetz CG, Stebbins GT, Höglinger GU (2020) The progressive supranuclear palsy clinical deficits scale. Movement Disord 35(4):650–661PubMed

go back to reference Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A, Querejeta-Coma A, Trenkwalder C, Sixel-Döring F, Foubert-Samier A, Le Traon AP, Plazzi G, Biscarini F, Montplaisir J, Gagnon J-F, Postuma RB, Antelmi E, Meissner WG, Mollenhauer B, Ben-Shlomo Y, Hu MT, Parkkinen L (2021) Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145(2):584–595PubMedCentral Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A, Querejeta-Coma A, Trenkwalder C, Sixel-Döring F, Foubert-Samier A, Le Traon AP, Plazzi G, Biscarini F, Montplaisir J, Gagnon J-F, Postuma RB, Antelmi E, Meissner WG, Mollenhauer B, Ben-Shlomo Y, Hu MT, Parkkinen L (2021) Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145(2):584–595PubMedCentral

go back to reference Postuma RB, Berg D (2016) Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12(11):622–634PubMed Postuma RB, Berg D (2016) Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12(11):622–634PubMed

go back to reference Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disord 30(12):1591–1601PubMed Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disord 30(12):1591–1601PubMed

go back to reference Postuma RB, Iranzo A, Hu M, Högl B, Boeve BF, Manni R, Oertel WH, Arnulf I, Ferini-Strambi L, Puligheddu M, Antelmi E, Cochen De Cock V, Arnaldi D, Mollenhauer B, Videnovic A, Sonka K, Jung K-Y, Kunz D, Dauvilliers Y, Provini F, Lewis SJ, Buskova J, Pavlova M, Heidbreder A, Montplaisir JY, Santamaria J, Barber TR, Stefani A, St Louis EK, Terzaghi M, Janzen A, Leu-Semenescu S, Plazzi G, Nobili F, Sixel-Doering F, Dusek P, Bes F, Cortelli P, Ehgoetz Martens K, Gagnon J-F, Gaig C, Zucconi M, Trenkwalder C, Gan-Or Z, Lo C, Rolinski M, Mahlknecht P, Holzknecht E, Boeve AR, Teigen LN, Toscano G, Mayer G, Morbelli S, Dawson B, Pelletier A (2019) Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 142(3):744–759PubMedPubMedCentral Postuma RB, Iranzo A, Hu M, Högl B, Boeve BF, Manni R, Oertel WH, Arnulf I, Ferini-Strambi L, Puligheddu M, Antelmi E, Cochen De Cock V, Arnaldi D, Mollenhauer B, Videnovic A, Sonka K, Jung K-Y, Kunz D, Dauvilliers Y, Provini F, Lewis SJ, Buskova J, Pavlova M, Heidbreder A, Montplaisir JY, Santamaria J, Barber TR, Stefani A, St Louis EK, Terzaghi M, Janzen A, Leu-Semenescu S, Plazzi G, Nobili F, Sixel-Doering F, Dusek P, Bes F, Cortelli P, Ehgoetz Martens K, Gagnon J-F, Gaig C, Zucconi M, Trenkwalder C, Gan-Or Z, Lo C, Rolinski M, Mahlknecht P, Holzknecht E, Boeve AR, Teigen LN, Toscano G, Mayer G, Morbelli S, Dawson B, Pelletier A (2019) Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 142(3):744–759PubMedPubMedCentral

go back to reference Pötter-Nerger M, Dutke J, Lezius S, Buhmann C, Schulz R, Gerloff C, Kuhle J, Choe C-U (2022) Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson’s disease in the MARK-PD study. J Neural Transmission (vienna, Austria: 1996) 129(3):295–300 Pötter-Nerger M, Dutke J, Lezius S, Buhmann C, Schulz R, Gerloff C, Kuhle J, Choe C-U (2022) Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson’s disease in the MARK-PD study. J Neural Transmission (vienna, Austria: 1996) 129(3):295–300

go back to reference Prell T, Siebecker F, Lorrain M, Eggers C, Lorenzl S, Klucken J, Warnecke T, Buhmann C, Tönges L, Ehret R, Wellach I, Wolz M (2020a) Recommendations for standards of network care for patients with Parkinson’s disease in Germany. J Clin Med 9(5):1455PubMedCentral Prell T, Siebecker F, Lorrain M, Eggers C, Lorenzl S, Klucken J, Warnecke T, Buhmann C, Tönges L, Ehret R, Wellach I, Wolz M (2020a) Recommendations for standards of network care for patients with Parkinson’s disease in Germany. J Clin Med 9(5):1455PubMedCentral

go back to reference Prell T, Siebecker F, Lorrain M, Tönges L, Warnecke T, Klucken J, Wellach I, Buhmann C, Wolz M, Lorenzl S, Herbst H, Eggers C, Mai T (2020b) Specialized staff for the care of people with Parkinson’s disease in Germany: an overview. J Clin Med 9(8):2581PubMedCentral Prell T, Siebecker F, Lorrain M, Tönges L, Warnecke T, Klucken J, Wellach I, Buhmann C, Wolz M, Lorenzl S, Herbst H, Eggers C, Mai T (2020b) Specialized staff for the care of people with Parkinson’s disease in Germany: an overview. J Clin Med 9(8):2581PubMedCentral

go back to reference Rabadia SV, Litvan I, Juncos J, Bordelon Y, Riley DE, Standaert D, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J (2019) Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord 66:166–170PubMed Rabadia SV, Litvan I, Juncos J, Bordelon Y, Riley DE, Standaert D, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J (2019) Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord 66:166–170PubMed

go back to reference Rajput AH, Rajput ML, Ferguson LW, Rajput A (2017) Baseline motor findings and Parkinson disease prognostic subtypes. Neurology 89(2):138–143PubMedPubMedCentral Rajput AH, Rajput ML, Ferguson LW, Rajput A (2017) Baseline motor findings and Parkinson disease prognostic subtypes. Neurology 89(2):138–143PubMedPubMedCentral

go back to reference Rajput AH, Sitte HH, Rajput A, Fenton ME, Pifl C, Hornykiewicz O (2008) Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 70(16 Pt 2):1403–1410PubMed Rajput AH, Sitte HH, Rajput A, Fenton ME, Pifl C, Hornykiewicz O (2008) Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 70(16 Pt 2):1403–1410PubMed

go back to reference Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A (2009) Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 73(3):206–212PubMed Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A (2009) Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 73(3):206–212PubMed

go back to reference Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW (2011) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 10(5):415–423PubMed Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW (2011) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 10(5):415–423PubMed

go back to reference Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, Leshuk C, Hernandez I, Wegmann S, Hyman BT, Gradinaru V, Kampmann M, Kosik KS (2020) LRP1 is a master regulator of tau uptake and spread. Nature 580(7803):381–385PubMedPubMedCentral Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, Leshuk C, Hernandez I, Wegmann S, Hyman BT, Gradinaru V, Kampmann M, Kosik KS (2020) LRP1 is a master regulator of tau uptake and spread. Nature 580(7803):381–385PubMedPubMedCentral

go back to reference Respondek G, Höglinger GU (2016) The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism Relat Disord 22(Suppl 1):S34–S36PubMed Respondek G, Höglinger GU (2016) The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism Relat Disord 22(Suppl 1):S34–S36PubMed

go back to reference Respondek G, Höglinger GU (2021) DescribePSP and ProPSP: German multicenter networks for standardized prospective collection of clinical data, imaging data, and biomaterials of patients with progressive supranuclear palsy. Front Neurol 12:644064PubMedPubMedCentral Respondek G, Höglinger GU (2021) DescribePSP and ProPSP: German multicenter networks for standardized prospective collection of clinical data, imaging data, and biomaterials of patients with progressive supranuclear palsy. Front Neurol 12:644064PubMedPubMedCentral

go back to reference Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol J-C, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU (2017) Which ante mortem clinical features predict progressive supranuclear palsy pathology? Movement Disord 32(7):995–1005PubMed Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol J-C, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU (2017) Which ante mortem clinical features predict progressive supranuclear palsy pathology? Movement Disord 32(7):995–1005PubMed

go back to reference Respondek G, Stamelou M, Höglinger GU (2019) Classification of atypical Parkinsonism per pathology versus phenotype. Int Rev Neurobiol 149:37–47PubMed Respondek G, Stamelou M, Höglinger GU (2019) Classification of atypical Parkinsonism per pathology versus phenotype. Int Rev Neurobiol 149:37–47PubMed

go back to reference Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ, van Swieten JC, Troakes C, Al Sarraj S, Gelpi E, Gaig C, Tolosa E, Oertel WH, Giese A, Roeber S, Arzberger T, Wagenpfeil S, Höglinger GU (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Movement Disord 29(14):1758–1766PubMed Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ, van Swieten JC, Troakes C, Al Sarraj S, Gelpi E, Gaig C, Tolosa E, Oertel WH, Giese A, Roeber S, Arzberger T, Wagenpfeil S, Höglinger GU (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Movement Disord 29(14):1758–1766PubMed

go back to reference Richards M, Marder K, Cote L, Mayeux R (1994) Interrater reliability of the Unified Parkinson’s disease rating scale motor examination. Movement Disord 9(1):89–91PubMed Richards M, Marder K, Cote L, Mayeux R (1994) Interrater reliability of the Unified Parkinson’s disease rating scale motor examination. Movement Disord 9(1):89–91PubMed

go back to reference Rojas JC, Bang J, Lobach IV, Tsai RM, Rabinovici GD, Miller BL, Boxer AL (2018) CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 90(4):e273–e281PubMedPubMedCentral Rojas JC, Bang J, Lobach IV, Tsai RM, Rabinovici GD, Miller BL, Boxer AL (2018) CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 90(4):e273–e281PubMedPubMedCentral

go back to reference Rösler TW, Tayaranian Marvian A, Brendel M, Nykänen N-P, Höllerhage M, Schwarz SC, Hopfner F, Koeglsperger T, Respondek G, Schweyer K, Levin J, Villemagne VL, Barthel H, Sabri O, Müller U, Meissner WG, Kovacs GG, Höglinger GU (2019) Four-repeat tauopathies. Prog Neurobiol 180:101644PubMed Rösler TW, Tayaranian Marvian A, Brendel M, Nykänen N-P, Höllerhage M, Schwarz SC, Hopfner F, Koeglsperger T, Respondek G, Schweyer K, Levin J, Villemagne VL, Barthel H, Sabri O, Müller U, Meissner WG, Kovacs GG, Höglinger GU (2019) Four-repeat tauopathies. Prog Neurobiol 180:101644PubMed

go back to reference Rossi M, Candelise N, Baiardi S, Capellari S, Giannini G, Orrù CD, Antelmi E, Mammana A, Hughson AG, Calandra-Buonaura G, Ladogana A, Plazzi G, Cortelli P, Caughey B, Parchi P (2020) Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 140(1):49–62PubMedPubMedCentral Rossi M, Candelise N, Baiardi S, Capellari S, Giannini G, Orrù CD, Antelmi E, Mammana A, Hughson AG, Calandra-Buonaura G, Ladogana A, Plazzi G, Cortelli P, Caughey B, Parchi P (2020) Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 140(1):49–62PubMedPubMedCentral

go back to reference Russo MJ, Orru CD, Concha-Marambio L, Giaisi S, Groveman BR, Farris CM, Holguin B, Hughson AG, LaFontant D-E, Caspell-Garcia C, Coffey CS, Mollon J, Hutten SJ, Merchant K, Heym RG, Soto C, Caughey B, Kang UJ (2021) High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease. Acta Neuropathol Commun 9(1):179PubMedPubMedCentral Russo MJ, Orru CD, Concha-Marambio L, Giaisi S, Groveman BR, Farris CM, Holguin B, Hughson AG, LaFontant D-E, Caspell-Garcia C, Coffey CS, Mollon J, Hutten SJ, Merchant K, Heym RG, Soto C, Caughey B, Kang UJ (2021) High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease. Acta Neuropathol Commun 9(1):179PubMedPubMedCentral

go back to reference Safarpour D, Thibault DP, DeSanto CL, Boyd CM, Dorsey ER, Racette BA, Willis AW (2015) Nursing home and end-of-life care in Parkinson disease. Neurology 85(5):413–419PubMedPubMedCentral Safarpour D, Thibault DP, DeSanto CL, Boyd CM, Dorsey ER, Racette BA, Willis AW (2015) Nursing home and end-of-life care in Parkinson disease. Neurology 85(5):413–419PubMedPubMedCentral

go back to reference Saranza G, Villanueva EQ, Lang AE (2021) Preferences for communication about end-of-life care in atypical Parkinsonism. Movement Disord 36(9):2116–2125PubMed Saranza G, Villanueva EQ, Lang AE (2021) Preferences for communication about end-of-life care in atypical Parkinsonism. Movement Disord 36(9):2116–2125PubMed

go back to reference Schrag A, Hommel ALAJ, Lorenzl S, Meissner WG, Odin P, Coelho M, Bloem BR, Dodel R (2020) The late stage of Parkinson’s -results of a large multinational study on motor and non-motor complications. Parkinsonism Relat Disord 75:91–96PubMed Schrag A, Hommel ALAJ, Lorenzl S, Meissner WG, Odin P, Coelho M, Bloem BR, Dodel R (2020) The late stage of Parkinson’s -results of a large multinational study on motor and non-motor complications. Parkinsonism Relat Disord 75:91–96PubMed

go back to reference Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, Gnjidic D, Del Mar CB, Roughead EE, Page A, Jansen J, Martin JH (2015) Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 175(5):827–834PubMed Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, Gnjidic D, Del Mar CB, Roughead EE, Page A, Jansen J, Martin JH (2015) Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 175(5):827–834PubMed

go back to reference Seeber AA, Pols AJ, Hijdra A, Grupstra HF, Willems DL, de Visser M (2019) Advance care planning in progressive neurological diseases: lessons from ALS. BMC Palliat Care 18(1):50PubMedPubMedCentral Seeber AA, Pols AJ, Hijdra A, Grupstra HF, Willems DL, de Visser M (2019) Advance care planning in progressive neurological diseases: lessons from ALS. BMC Palliat Care 18(1):50PubMedPubMedCentral

go back to reference Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, Hu B, Schmeichel A, Singer W, Wu G, Tsai A-L, Shirani H, Nilsson KPR, Low PA, Soto C (2020) Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 578:273–277PubMedPubMedCentral Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, Hu B, Schmeichel A, Singer W, Wu G, Tsai A-L, Shirani H, Nilsson KPR, Low PA, Soto C (2020) Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 578:273–277PubMedPubMedCentral

go back to reference Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, van Beers M, Tarutani A, Kametani F, Garringer HJ, Vidal R, Hallinan GI, Lashley T, Saito Y, Murayama S, Yoshida M, Tanaka H, Kakita A, Ikeuchi T, Robinson AC, Mann DMA, Kovacs GG, Revesz T, Ghetti B, Hasegawa M, Goedert M, Scheres SHW (2021) Structure-based classification of tauopathies. Nature 598(7880):359–363PubMedPubMedCentral Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, van Beers M, Tarutani A, Kametani F, Garringer HJ, Vidal R, Hallinan GI, Lashley T, Saito Y, Murayama S, Yoshida M, Tanaka H, Kakita A, Ikeuchi T, Robinson AC, Mann DMA, Kovacs GG, Revesz T, Ghetti B, Hasegawa M, Goedert M, Scheres SHW (2021) Structure-based classification of tauopathies. Nature 598(7880):359–363PubMedPubMedCentral

go back to reference Simonet C, Schrag A, Lees AJ, Noyce AJ (2021) The motor prodromes of parkinson’s disease: from bedside observation to large-scale application. J Neurol 268(6):2099–2108PubMed Simonet C, Schrag A, Lees AJ, Noyce AJ (2021) The motor prodromes of parkinson’s disease: from bedside observation to large-scale application. J Neurol 268(6):2099–2108PubMed

go back to reference Singer W, Schmeichel AM, Shahnawaz M, Schmelzer JD, Sletten DM, Gehrking TL, Gehrking JA, Olson AD, Suarez MD, Misra PP, Soto C, Low PA (2021) Alpha-synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Ann Neurol 89(6):1212–1220PubMedPubMedCentral Singer W, Schmeichel AM, Shahnawaz M, Schmelzer JD, Sletten DM, Gehrking TL, Gehrking JA, Olson AD, Suarez MD, Misra PP, Soto C, Low PA (2021) Alpha-synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Ann Neurol 89(6):1212–1220PubMedPubMedCentral

go back to reference Song M, Scheifele M, Barthel H, van Eimeren T, Beyer L, Marek K, Eckenweber F, Palleis C, Kaiser L, Finze A, Kern M, Nitschmann A, Biechele G, Katzdobler S, Bischof G, Hammes J, Jessen F, Saur D, Schroeter ML, Rumpf J-J, Rullmann M, Schildan A, Patt M, Neumaier B, Stephens AW, Rauchmann B-S, Perneczky R, Levin J, Classen J, Höglinger GU, Bartenstein P, Boening G, Ziegler S, Villemagne V, Drzezga A, Seibyl J, Sabri O, Brendel M (2021) Feasibility of short imaging protocols for 18FPI-2620 tau-PET in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging 48(12):3872–3885PubMedPubMedCentral Song M, Scheifele M, Barthel H, van Eimeren T, Beyer L, Marek K, Eckenweber F, Palleis C, Kaiser L, Finze A, Kern M, Nitschmann A, Biechele G, Katzdobler S, Bischof G, Hammes J, Jessen F, Saur D, Schroeter ML, Rumpf J-J, Rullmann M, Schildan A, Patt M, Neumaier B, Stephens AW, Rauchmann B-S, Perneczky R, Levin J, Classen J, Höglinger GU, Bartenstein P, Boening G, Ziegler S, Villemagne V, Drzezga A, Seibyl J, Sabri O, Brendel M (2021) Feasibility of short imaging protocols for 18FPI-2620 tau-PET in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging 48(12):3872–3885PubMedPubMedCentral

go back to reference Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839–840PubMed Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839–840PubMed

go back to reference Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, Shi M, Zhang J (2014) Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 184(4):966–975PubMedPubMedCentral Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, Shi M, Zhang J (2014) Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 184(4):966–975PubMedPubMedCentral

go back to reference Taguchi YV, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, Keutzer J, Mistry PK, Chandra SS (2017) Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-Associated Parkinson’s disease. J Neurosci 37(40):9617–9631PubMedPubMedCentral Taguchi YV, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, Keutzer J, Mistry PK, Chandra SS (2017) Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-Associated Parkinson’s disease. J Neurosci 37(40):9617–9631PubMedPubMedCentral

go back to reference Tennigkeit J, Feige T, Haak M, Hellqvist C, Seven ÜS, Kalbe E, Schwarz J, Warnecke T, Tönges L, Eggers C, Loewenbrück KF (2020) Structured care and self-management education for persons with parkinson’s disease: why the first does not go without the second-systematic review, experiences and implementation concepts from Sweden and Germany. J Clin Med 9(9):2787PubMedCentral Tennigkeit J, Feige T, Haak M, Hellqvist C, Seven ÜS, Kalbe E, Schwarz J, Warnecke T, Tönges L, Eggers C, Loewenbrück KF (2020) Structured care and self-management education for persons with parkinson’s disease: why the first does not go without the second-systematic review, experiences and implementation concepts from Sweden and Germany. J Clin Med 9(9):2787PubMedCentral

go back to reference Tessitore A, Marano P, Modugno N, Pontieri FE, Tambasco N, Canesi M, Latorre A, Lopiano L, Sensi M, Quatrale R, Solla P, Defazio G, Melzi G, Costanzo AM, Gualberti G, Di Luzio PU, Antonini A (2018) Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study. J Neurol 265(5):1124–1137PubMedPubMedCentral Tessitore A, Marano P, Modugno N, Pontieri FE, Tambasco N, Canesi M, Latorre A, Lopiano L, Sensi M, Quatrale R, Solla P, Defazio G, Melzi G, Costanzo AM, Gualberti G, Di Luzio PU, Antonini A (2018) Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study. J Neurol 265(5):1124–1137PubMedPubMedCentral

go back to reference Trapp S, MacKenzie J, Gonzalez-Arredondo S, Rodriguez-Agudelo Y, Arango-Lasprilla JC (2019) Mediating role of caregiver burden among family caregivers of patients with Parkinson’s disease in Mexico. Int J Psychiatry Med 54(3):203–216PubMed Trapp S, MacKenzie J, Gonzalez-Arredondo S, Rodriguez-Agudelo Y, Arango-Lasprilla JC (2019) Mediating role of caregiver burden among family caregivers of patients with Parkinson’s disease in Mexico. Int J Psychiatry Med 54(3):203–216PubMed

go back to reference Truong D-JJ, Phlairaharn T, Eßwein B, Gruber C, Tümen D, Baligács E, Armbrust N, Vaccaro FL, Lederer E-M, Beck EM, Geilenkeuser J, Göppert S, Krumwiede L, Grätz C, Raffl G, Schwarz D, Zirngibl M, Živanić M, Beyer M, Körner JD, Santl T, Evsyukov V, Strauß T, Schwarz SC, Höglinger GU, Heutink P, Doll S, Conrad M, Giesert F, Wurst W, Westmeyer GG (2021) Non-invasive and high-throughput interrogation of exon-specific isoform expression. Nat Cell Biol 23(6):652–663PubMedPubMedCentral Truong D-JJ, Phlairaharn T, Eßwein B, Gruber C, Tümen D, Baligács E, Armbrust N, Vaccaro FL, Lederer E-M, Beck EM, Geilenkeuser J, Göppert S, Krumwiede L, Grätz C, Raffl G, Schwarz D, Zirngibl M, Živanić M, Beyer M, Körner JD, Santl T, Evsyukov V, Strauß T, Schwarz SC, Höglinger GU, Heutink P, Doll S, Conrad M, Giesert F, Wurst W, Westmeyer GG (2021) Non-invasive and high-throughput interrogation of exon-specific isoform expression. Nat Cell Biol 23(6):652–663PubMedPubMedCentral

go back to reference Türker F, Cook EK, Margolis SS (2021) The proteasome and its role in the nervous system. Cell Chem Biol 28(7):903–917PubMedPubMedCentral Türker F, Cook EK, Margolis SS (2021) The proteasome and its role in the nervous system. Cell Chem Biol 28(7):903–917PubMedPubMedCentral

go back to reference Uemura N, Uemura MT, Luk KC, Lee VM-Y, Trojanowski JQ (2020) Cell-to-cell transmission of tau and α-Synuclein. Trends Mol Med 26(10):936–952PubMedPubMedCentral Uemura N, Uemura MT, Luk KC, Lee VM-Y, Trojanowski JQ (2020) Cell-to-cell transmission of tau and α-Synuclein. Trends Mol Med 26(10):936–952PubMedPubMedCentral

go back to reference van Rooden SM, Heiser WJ, Kok JN, Verbaan D, van Hilten JJ, Marinus J (2010) The identification of Parkinson’s disease subtypes using cluster analysis: a systematic review. Movement Disord 25(8):969–978PubMed van Rooden SM, Heiser WJ, Kok JN, Verbaan D, van Hilten JJ, Marinus J (2010) The identification of Parkinson’s disease subtypes using cluster analysis: a systematic review. Movement Disord 25(8):969–978PubMed

go back to reference Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC (2018) Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol 14(4):225–236PubMed Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC (2018) Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol 14(4):225–236PubMed

go back to reference Viscidi E, Litvan I, Dam T, Juneja M, Li L, Krzywy H, Eaton S, Hall S, Kupferman J, Höglinger GU (2021) Clinical features of patients with progressive supranuclear palsy in an US insurance claims database. Front Neurol 12:571800PubMedPubMedCentral Viscidi E, Litvan I, Dam T, Juneja M, Li L, Krzywy H, Eaton S, Hall S, Kupferman J, Höglinger GU (2021) Clinical features of patients with progressive supranuclear palsy in an US insurance claims database. Front Neurol 12:571800PubMedPubMedCentral

go back to reference Wagner J, Krauss S, Shi S, Ryazanov S, Steffen J, Miklitz C, Leonov A, Kleinknecht A, Göricke B, Weishaupt JH, Weckbecker D, Reiner AM, Zinth W, Levin J, Ehninger D, Remy S, Kretzschmar HA, Griesinger C, Giese A, Fuhrmann M (2015) Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol 130(5):619–631PubMedPubMedCentral Wagner J, Krauss S, Shi S, Ryazanov S, Steffen J, Miklitz C, Leonov A, Kleinknecht A, Göricke B, Weishaupt JH, Weckbecker D, Reiner AM, Zinth W, Levin J, Ehninger D, Remy S, Kretzschmar HA, Griesinger C, Giese A, Fuhrmann M (2015) Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol 130(5):619–631PubMedPubMedCentral

go back to reference Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, Bertsch U, Mitteregger-Kretzschmar G, Geissen M, Eiden M, Leidel F, Hirschberger T, Deeg AA, Krauth JJ, Zinth W, Tavan P, Pilger J, Zweckstetter M, Frank T, Bähr M, Weishaupt JH, Uhr M, Urlaub H, Teichmann U, Samwer M, Bötzel K, Groschup M, Kretzschmar H, Griesinger C, Giese A (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease. Acta Neuropathol 125(6):795–813PubMedPubMedCentral Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, Bertsch U, Mitteregger-Kretzschmar G, Geissen M, Eiden M, Leidel F, Hirschberger T, Deeg AA, Krauth JJ, Zinth W, Tavan P, Pilger J, Zweckstetter M, Frank T, Bähr M, Weishaupt JH, Uhr M, Urlaub H, Teichmann U, Samwer M, Bötzel K, Groschup M, Kretzschmar H, Griesinger C, Giese A (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease. Acta Neuropathol 125(6):795–813PubMedPubMedCentral

go back to reference Wenning GK, Stankovic I, Vignatelli L, Fanciulli A, Calandra-Buonaura G, Seppi K, Palma J-A, Meissner WG, Krismer F, Berg D, Cortelli P, Freeman R, Halliday G, Höglinger G, Lang A, Ling H, Litvan I, Low P, Miki Y, Panicker J, Pellecchia MT, Quinn N, Sakakibara R, Stamelou M, Tolosa E, Tsuji S, Warner T, Poewe W, Kaufmann H (2022) The movement disorder society criteria for the diagnosis of multiple system atrophy. Movement Disord. https://doi.org/10.1002/mds.29005CrossRefPubMed Wenning GK, Stankovic I, Vignatelli L, Fanciulli A, Calandra-Buonaura G, Seppi K, Palma J-A, Meissner WG, Krismer F, Berg D, Cortelli P, Freeman R, Halliday G, Höglinger G, Lang A, Ling H, Litvan I, Low P, Miki Y, Panicker J, Pellecchia MT, Quinn N, Sakakibara R, Stamelou M, Tolosa E, Tsuji S, Warner T, Poewe W, Kaufmann H (2022) The movement disorder society criteria for the diagnosis of multiple system atrophy. Movement Disord. https://​doi.​org/​10.​1002/​mds.​29005CrossRefPubMed

go back to reference Winslow AR, Rubinsztein DC (2011) The Parkinson disease protein α-synuclein inhibits autophagy. Autophagy 7(4):429–431PubMedPubMedCentral Winslow AR, Rubinsztein DC (2011) The Parkinson disease protein α-synuclein inhibits autophagy. Autophagy 7(4):429–431PubMedPubMedCentral

go back to reference Zarit SH, Todd PA, Zarit JM (1986) Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist 26(3):260–266PubMed Zarit SH, Todd PA, Zarit JM (1986) Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist 26(3):260–266PubMed

go back to reference Zella MAS, Bartig D, Herrmann L, Respondek G, Höglinger G, Gold R, Woitalla D, Krogias C, Tönges L (2020) Hospitalization rates and comorbidities in patients with progressive supranuclear palsy in Germany from 2010 to 2017. J Clin Med 9(8):2454PubMedCentral Zella MAS, Bartig D, Herrmann L, Respondek G, Höglinger G, Gold R, Woitalla D, Krogias C, Tönges L (2020) Hospitalization rates and comorbidities in patients with progressive supranuclear palsy in Germany from 2010 to 2017. J Clin Med 9(8):2454PubMedCentral

go back to reference Zhang H, Iranzo A, Högl B, Arnulf I, Ferini-Strambi L, Manni R, Miyamoto T, Oertel WH, Dauvilliers Y, Ju Y-E, Puligheddu M, Sonka K, Pelletier A, Montplaisir JY, Stefani A, Ibrahim A, Frauscher B, Leu-Semenescu S, Zucconi M, Terzaghi M, Miyamoto M, Janzen A, Figorilli M, Fantini ML, Postuma RB (2022a) Risk factors for phenoconversion in rapid eye movement sleep behavior disorder. Ann Neurol 91(3):404–416PubMed Zhang H, Iranzo A, Högl B, Arnulf I, Ferini-Strambi L, Manni R, Miyamoto T, Oertel WH, Dauvilliers Y, Ju Y-E, Puligheddu M, Sonka K, Pelletier A, Montplaisir JY, Stefani A, Ibrahim A, Frauscher B, Leu-Semenescu S, Zucconi M, Terzaghi M, Miyamoto M, Janzen A, Figorilli M, Fantini ML, Postuma RB (2022a) Risk factors for phenoconversion in rapid eye movement sleep behavior disorder. Ann Neurol 91(3):404–416PubMed

go back to reference Zhang L, Cao B, Hou Y, Gu X, Wei Q, Ou R, Zhao B, Luo C, Shang H (2022b) Neurofilament light chain predicts disease severity and progression in multiple system atrophy. Movement Disord 37(2):421–426PubMed Zhang L, Cao B, Hou Y, Gu X, Wei Q, Ou R, Zhao B, Luo C, Shang H (2022b) Neurofilament light chain predicts disease severity and progression in multiple system atrophy. Movement Disord 37(2):421–426PubMed

go back to reference Zhang S, Liu Y-Q, Jia C, Lim Y-J, Feng G, Xu E, Long H, Kimura Y, Tao Y, Zhao C, Wang C, Liu Z, Hu J-J, Ma M-R, Liu Z, Jiang L, Li D, Wang R, Dawson VL, Dawson TM, Li Y-M, Mao X, Liu C (2021) Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson’s disease. Proc Natl Acad Sci USA 118(26):e2011196118PubMedPubMedCentral Zhang S, Liu Y-Q, Jia C, Lim Y-J, Feng G, Xu E, Long H, Kimura Y, Tao Y, Zhao C, Wang C, Liu Z, Hu J-J, Ma M-R, Liu Z, Jiang L, Li D, Wang R, Dawson VL, Dawson TM, Li Y-M, Mao X, Liu C (2021) Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson’s disease. Proc Natl Acad Sci USA 118(26):e2011196118PubMedPubMedCentral

go back to reference Zhang W, Tarutani A, Newell KL, Murzin AG, Matsubara T, Falcon B, Vidal R, Garringer HJ, Shi Y, Ikeuchi T, Murayama S, Ghetti B, Hasegawa M, Goedert M, Scheres SHW (2020) Novel tau filament fold in corticobasal degeneration. Nature 580(7802):283–287PubMedPubMedCentral Zhang W, Tarutani A, Newell KL, Murzin AG, Matsubara T, Falcon B, Vidal R, Garringer HJ, Shi Y, Ikeuchi T, Murayama S, Ghetti B, Hasegawa M, Goedert M, Scheres SHW (2020) Novel tau filament fold in corticobasal degeneration. Nature 580(7802):283–287PubMedPubMedCentral

go back to reference Zhong M, Evans A, Peppard R, Velakoulis D (2013) Validity and reliability of the PDCB: a tool for the assessment of caregiver burden in Parkinson’s disease. Int Psychogeriatr 25(9):1437–1441PubMed Zhong M, Evans A, Peppard R, Velakoulis D (2013) Validity and reliability of the PDCB: a tool for the assessment of caregiver burden in Parkinson’s disease. Int Psychogeriatr 25(9):1437–1441PubMed